{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8Q9A557bm7mU",
        "outputId": "ef71611b-b767-4cac-fb73-3c249fbdfa76"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Collecting groq\n",
            "  Downloading groq-0.36.0-py3-none-any.whl.metadata (16 kB)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.12/dist-packages (from groq) (4.11.0)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/local/lib/python3.12/dist-packages (from groq) (1.9.0)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.12/dist-packages (from groq) (0.28.1)\n",
            "Requirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.12/dist-packages (from groq) (2.11.10)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.12/dist-packages (from groq) (1.3.1)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.10 in /usr/local/lib/python3.12/dist-packages (from groq) (4.15.0)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.12/dist-packages (from anyio<5,>=3.5.0->groq) (3.11)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.12/dist-packages (from httpx<1,>=0.23.0->groq) (2025.11.12)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.12/dist-packages (from httpx<1,>=0.23.0->groq) (1.0.9)\n",
            "Requirement already satisfied: h11>=0.16 in /usr/local/lib/python3.12/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->groq) (0.16.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.12/dist-packages (from pydantic<3,>=1.9.0->groq) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.33.2 in /usr/local/lib/python3.12/dist-packages (from pydantic<3,>=1.9.0->groq) (2.33.2)\n",
            "Requirement already satisfied: typing-inspection>=0.4.0 in /usr/local/lib/python3.12/dist-packages (from pydantic<3,>=1.9.0->groq) (0.4.2)\n",
            "Downloading groq-0.36.0-py3-none-any.whl (137 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m137.3/137.3 kB\u001b[0m \u001b[31m3.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: groq\n",
            "Successfully installed groq-0.36.0\n"
          ]
        }
      ],
      "source": [
        "!pip install groq"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "RAAjswX6m_aO"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "from tqdm import tqdm\n",
        "\n",
        "import re\n",
        "import requests\n",
        "import json\n",
        "import time\n",
        "import copy\n",
        "from typing import Dict, Any"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gvVNpdFynApe",
        "outputId": "f07b132e-6c73-4956-94a4-66fd4ac7328f"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "Fetching lung cancer trials: 100trial [00:00, 201.95trial/s]"
          ]
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "\n",
            "Fetched 100 lung cancer trials\n",
            "Done!\n"
          ]
        },
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "\n"
          ]
        }
      ],
      "source": [
        "\n",
        "# ============= LUNG CANCER-ONLY FETCHER =============\n",
        "BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
        "\n",
        "def fetch_lung_cancer_trials(\n",
        "    page_size=10,\n",
        "    max_total=50,             \n",
        "    status_filter=None         # e.g., \"RECRUITING\", \"ACTIVE_NOT_RECRUITING\"\n",
        "):\n",
        "    params = {\n",
        "        \"format\": \"json\",\n",
        "        \"pageSize\": page_size,\n",
        "        # MeSH filter for lung neoplasms\n",
        "        \"filter.advanced\": \"AREA[ConditionMeshTerm]Neoplasms/Lung\",\n",
        "    }\n",
        "    if status_filter:\n",
        "        params[\"filter.status\"] = status_filter\n",
        "\n",
        "    all_studies = []\n",
        "    next_token = None\n",
        "    pbar = tqdm(desc=\"Fetching lung cancer trials\", unit=\"trial\")\n",
        "\n",
        "    while True:\n",
        "        if next_token:\n",
        "            params[\"pageToken\"] = next_token\n",
        "\n",
        "        resp = requests.get(BASE_URL, params=params, timeout=60)\n",
        "        resp.raise_for_status()\n",
        "        data = resp.json()\n",
        "\n",
        "        batch = data.get(\"studies\", [])\n",
        "        all_studies.extend(batch)\n",
        "        pbar.update(len(batch))\n",
        "\n",
        "        next_token = data.get(\"nextPageToken\")\n",
        "        if not next_token or (max_total and len(all_studies) >= max_total):\n",
        "            break\n",
        "\n",
        "        time.sleep(0.1)  # being polite to the API\n",
        "\n",
        "    pbar.close()\n",
        "    studies = all_studies[:max_total] if max_total else all_studies\n",
        "    print(f\"\\nFetched {len(studies)} lung cancer trials\")\n",
        "    return studies\n",
        "\n",
        "# Usage\n",
        "studies = fetch_lung_cancer_trials(\n",
        "    page_size=100,\n",
        "    max_total=100,\n",
        "    # status_filter=\"RECRUITING|ACTIVE_NOT_RECRUITING\"  # optional\n",
        ")\n",
        "\n",
        "# Save to file if needed\n",
        "# with open(\"lung_cancer_trials_2025.json\", \"w\", encoding=\"utf-8\") as f:\n",
        "#     json.dump(studies, f, indent=2)\n",
        "\n",
        "print(\"Done!\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 4,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "EVFAdHc7nCTs",
        "outputId": "41920741-4fb7-478e-ef27-ab9a5151457b"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Raw df shape: (100, 19)\n"
          ]
        }
      ],
      "source": [
        "# ============= Flatten helper =============\n",
        "def safe_get(d, path, default=\"\"):\n",
        "    for p in path:\n",
        "        if not isinstance(d, dict):\n",
        "            return default\n",
        "        d = d.get(p, default)\n",
        "    return d if d is not None else default\n",
        "\n",
        "records = []\n",
        "for s in studies:\n",
        "    ps = s.get(\"protocolSection\", {})\n",
        "    row = {\n",
        "        \"NCT_ID\": safe_get(ps, [\"identificationModule\", \"nctId\"]),\n",
        "        \"Title\": safe_get(ps, [\"identificationModule\", \"briefTitle\"]),\n",
        "        \"Official_Title\": safe_get(ps, [\"identificationModule\", \"officialTitle\"]),\n",
        "        \"Status\": safe_get(ps, [\"statusModule\", \"overallStatus\"]),\n",
        "        \"Start_Date\": safe_get(ps, [\"statusModule\", \"startDateStruct\", \"date\"]),\n",
        "        \"Primary_Completion\": safe_get(ps, [\"statusModule\", \"primaryCompletionDateStruct\", \"date\"]),\n",
        "        \"Study_Type\": safe_get(ps, [\"designModule\", \"studyType\"]),\n",
        "        \"Phases\": \", \".join(safe_get(ps, [\"designModule\", \"phases\"], [])) if isinstance(safe_get(ps, [\"designModule\", \"phases\"], []), list) else safe_get(ps, [\"designModule\", \"phases\"], \"\"),\n",
        "        \"Enrollment\": safe_get(ps, [\"designModule\", \"enrollmentInfo\", \"count\"]),\n",
        "        \"Conditions\": \", \".join(safe_get(ps, [\"conditionsModule\", \"conditions\"], [])) if isinstance(safe_get(ps, [\"conditionsModule\", \"conditions\"], []), list) else safe_get(ps, [\"conditionsModule\", \"conditions\"], \"\"),\n",
        "        \"Sex\": safe_get(ps, [\"eligibilityModule\", \"sex\"]),\n",
        "        \"Min_Age\": safe_get(ps, [\"eligibilityModule\", \"minimumAge\"]),\n",
        "        \"Max_Age\": safe_get(ps, [\"eligibilityModule\", \"maximumAge\"]),\n",
        "        \"Lead_Sponsor\": safe_get(ps, [\"sponsorCollaboratorsModule\", \"leadSponsor\", \"name\"]),\n",
        "        \"Brief_Summary\": safe_get(ps, [\"descriptionModule\", \"briefSummary\"]),\n",
        "        \"Eligibility\": safe_get(ps, [\"eligibilityModule\", \"eligibilityCriteria\"]),\n",
        "    }\n",
        "    # outcomes & interventions\n",
        "    prim = safe_get(ps, [\"outcomesModule\", \"primaryOutcomes\"], [])\n",
        "    row[\"Primary_Measures\"] = \" | \".join([p.get(\"measure\", \"\") for p in prim]) if prim else \"\"\n",
        "    sec = safe_get(ps, [\"outcomesModule\", \"secondaryOutcomes\"], [])\n",
        "    row[\"Secondary_Measures\"] = \" | \".join([p.get(\"measure\", \"\") for p in sec]) if sec else \"\"\n",
        "    ints = safe_get(ps, [\"armsInterventionsModule\", \"interventions\"], [])\n",
        "    row[\"Interventions\"] = \" | \".join([f\"{i.get('type','')}:{i.get('name','')}\" for i in ints]) if ints else \"\"\n",
        "    records.append(row)\n",
        "\n",
        "df = pd.DataFrame(records)\n",
        "print(\"Raw df shape:\", df.shape)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 5,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "FFleAaq4nGGk",
        "outputId": "c9cb86a6-b8f2-42a1-aa09-b5352ffd9ef8"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "After filtering short elig texts: (100, 20)\n"
          ]
        }
      ],
      "source": [
        "# ============= Clean text ============\n",
        "def clean_text(t):\n",
        "    if not isinstance(t, str): return \"\"\n",
        "    t = re.sub(r\"\\s+\", \" \", t)\n",
        "    t = re.sub(r\"[•\\n\\t\\r]\", \" \", t)\n",
        "    t = re.sub(r\"\\(Version [^\\)]*\\)\", \"\", t)\n",
        "    return t.strip()\n",
        "\n",
        "for col in [\"Title\", \"Brief_Summary\", \"Official_Title\", \"Eligibility\"]:\n",
        "    if col in df.columns:\n",
        "        df[col] = df[col].apply(clean_text)\n",
        "\n",
        "# optional: drop trials that have no eligibility text or extremely short eligibility\n",
        "df[\"elig_len\"] = df[\"Eligibility\"].apply(lambda x: len(x or \"\"))\n",
        "# df = df[df[\"elig_len\"] > 50].copy()\n",
        "print(\"After filtering short elig texts:\", df.shape)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "D3nsBZWqnHtf"
      },
      "outputs": [],
      "source": [
        "# pd.set_option('display.max_colwidth', None)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "metadata": {
        "id": "0QmLgrHDnJD2"
      },
      "outputs": [],
      "source": [
        "pd.reset_option('display.max_colwidth')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 7,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "XYh6hI9eFund",
        "outputId": "32a9c46d-5beb-4590-e7b1-b499957ed30f"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 100,\n  \"fields\": [\n    {\n      \"column\": \"NCT_ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"NCT03007953\",\n          \"NCT06997458\",\n          \"NCT05256290\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II\",\n          \"Liquid BiOpsy, Lung and Colon Cancer in AndaluciA\",\n          \"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Official_Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II\",\n          \"Clinical Implementation of Liquid Biopsy in Cancer Through Next Generation Sequencing (NGS) Panels in the Andalusian Public Health System\",\n          \"A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10,\n        \"samples\": [\n          \"ENROLLING_BY_INVITATION\",\n          \"COMPLETED\",\n          \"NOT_YET_RECRUITING\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Start_Date\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 96,\n        \"samples\": [\n          \"2016-12-05\",\n          \"2015-05\",\n          \"2020-09-24\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_Completion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 91,\n        \"samples\": [\n          \"2021-09-01\",\n          \"2025-03-14\",\n          \"2024-05-27\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study_Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"INTERVENTIONAL\",\n          \"OBSERVATIONAL\",\n          \"EXPANDED_ACCESS\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"PHASE2, PHASE3\",\n          \"PHASE2\",\n          \"PHASE1, PHASE2\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"1970-01-01 00:00:00\",\n        \"max\": \"1970-01-01 00:00:00.001000\",\n        \"num_unique_values\": 72,\n        \"samples\": [\n          0,\n          62,\n          133\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 75,\n        \"samples\": [\n          \"Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer\",\n          \"Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer, Metastatic Lung Cancer, Metastatic Ovary Cancer, Oesophageal Cancer, Endometrial Cancer, Advanced Solid Tumor\",\n          \"Segmentectomy\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"FEMALE\",\n          \"ALL\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Min_Age\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 11,\n        \"samples\": [\n          \"20 Years\",\n          \"18 Years\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Max_Age\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 13,\n        \"samples\": [\n          \"99 Years\",\n          \"120 Years\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Lead_Sponsor\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 84,\n        \"samples\": [\n          \"Norwegian University of Science and Technology\",\n          \"VM Oncology, LLC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Brief_Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"The focus of the study is to test a nurse-led telephone-based palliative care intervention on improving the delivery of care for patients with newly diagnosed lung cancer. The study is a three site randomized control trial to determine the efficacy of the intervention on improving patients' quality of life, symptom burden, and satisfaction of care. Additionally, the study will test an innovative care delivery model to improve patients' access to palliative care. The investigators will also determine the effect of the intervention on patient activation to discuss treatment preferences with their clinician and on clinician knowledge of patients' goals of care.\",\n          \"The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Eligibility\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"Inclusion Criteria: Patients diagnosed at the Puget Sound Health Care System, Birmingham VA, or Portland VA with a primary diagnosis of lung cancer that requires more than surgical resection: * diagnosed within 8 weeks of recruitment * must have telephone access * ability to understand English * able to participate in informed consent process Exclusion Criteria: Patients not eligible to participate in the study include those who are inpatients prior to randomization, * those who are under the care of palliative care or hospice at the time of randomization * those who have severe mental health disorders * those who are unable to speak directly with the nurse over the telephone * or those that have the inability to provide informed consent\",\n          \"Inclusion Criteria: General criteria: * More than 18 years old * Both genders * Ability to provide written informed consent Specific criteria: * NSCLC * Patients diagnosed with the 8th Edition of the Tumor, Node, Metastasis (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c) * Histologically confirmed NSCLC (adenocarcinoma) * Performance status of 0-2 (ECOG PS) \\u25cb Estimated life expectancy \\u22653 months * Treatment na\\u00efve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy). * Smokers or Non-Smokers * CRC * Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c) * Histologically confirmed CRC (adenocarcinoma) * Performance status of 0-2 (ECOG PS) * Estimated life expectancy \\u22653 months * Treatment na\\u00efve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy). Exclusion Criteria: * General: History of any other cancer within the previous 5 years, except non-melanoma skin cancer * General: Absence of Informed consent. \\\\> Pregnant or nursing women. \\\\> Small cell lung cancer.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 95,\n        \"samples\": [\n          \"Overall Intracranial Response Rate (OIRR) in Cohort 1 by Blinded Independent Review Committee (BIRC) review\",\n          \"Number of patients with local and/or regional relapse\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 74,\n        \"samples\": [\n          \"Incidence of dosimetrically sparing one or both ovaries from a functionally ablative radiation dose\",\n          \"Change From Baseline in Patient Satisfaction of Care at Final Visit\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Interventions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 91,\n        \"samples\": [\n          \"DRUG:Chemotherapy | OTHER:Functional Assessment | OTHER:Questionnaire Administration\",\n          \"DRUG:bevacizumab + erlotinib hydrochloride | DRUG:gemcitabine hydrochloride + cisplatin or carboplatin\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"elig_len\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2432,\n        \"min\": 64,\n        \"max\": 14748,\n        \"num_unique_values\": 99,\n        \"samples\": [\n          535,\n          792\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-7210e363-3571-4aaf-81e6-9cc802ef1276\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Official_Title</th>\n",
              "      <th>Status</th>\n",
              "      <th>Start_Date</th>\n",
              "      <th>Primary_Completion</th>\n",
              "      <th>Study_Type</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Min_Age</th>\n",
              "      <th>Max_Age</th>\n",
              "      <th>Lead_Sponsor</th>\n",
              "      <th>Brief_Summary</th>\n",
              "      <th>Eligibility</th>\n",
              "      <th>Primary_Measures</th>\n",
              "      <th>Secondary_Measures</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>elig_len</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT03556228</td>\n",
              "      <td>Selective TrkA Inhibitor VMD-928 to Treat TrkA...</td>\n",
              "      <td>An Open-Label, Multiple-Dose, Dose-Escalation ...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2018-06-08</td>\n",
              "      <td>2026-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>82</td>\n",
              "      <td>Head and Neck Carcinoma, Adenoid Cystic Carcin...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>VM Oncology, LLC</td>\n",
              "      <td>This is a multicenter, open-label, Phase 1 stu...</td>\n",
              "      <td>Key Inclusion Criteria: * Histologically or cy...</td>\n",
              "      <td>Number and severity of treatment-emergent Adve...</td>\n",
              "      <td>Area under the plasma concentration versus tim...</td>\n",
              "      <td>DRUG:VMD-928 300 mg Tablet (ongoing); 100 mg C...</td>\n",
              "      <td>4124</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00009971</td>\n",
              "      <td>Fenretinide in Treating Patients With Recurren...</td>\n",
              "      <td>Phase II Trial Of Fenretinide (NSC-374551; IND...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2000-11</td>\n",
              "      <td>2005-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>32</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Phase II trial to study the effectiveness of f...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or c...</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>DRUG:fenretinide</td>\n",
              "      <td>1815</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT00260871</td>\n",
              "      <td>Genetic Epidemiological Study of Lung Cancer i...</td>\n",
              "      <td>Genetic Epidemiological Study of Lung Cancer i...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2002-05</td>\n",
              "      <td></td>\n",
              "      <td>OBSERVATIONAL</td>\n",
              "      <td></td>\n",
              "      <td>1500</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>National Health Research Institutes, Taiwan</td>\n",
              "      <td>Lung adenocarcinoma in Chinese females is hypo...</td>\n",
              "      <td>Inclusion Criteria: * lung adenocarcinoma Excl...</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT00721981</td>\n",
              "      <td>An Evaluation of the Clinical Treatment and Pa...</td>\n",
              "      <td>A Non-interventional Study for Evaluation of t...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2009-04</td>\n",
              "      <td></td>\n",
              "      <td>OBSERVATIONAL</td>\n",
              "      <td></td>\n",
              "      <td>120</td>\n",
              "      <td>Lung Cancer, Non-small Cell Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>AstraZeneca</td>\n",
              "      <td>The main purpose of this study is the identifi...</td>\n",
              "      <td>Inclusion Criteria: * Patients suffering from ...</td>\n",
              "      <td>To obtain patient preferences in direct correl...</td>\n",
              "      <td>current medical practice treatment objectives ...</td>\n",
              "      <td></td>\n",
              "      <td>646</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT03167281</td>\n",
              "      <td>Early Intrapleural TPA Instillation Versus Late</td>\n",
              "      <td>Early Intrapleural TPA Instillation Versus Late</td>\n",
              "      <td>WITHDRAWN</td>\n",
              "      <td>2017-02-17</td>\n",
              "      <td>2021-03-10</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE4</td>\n",
              "      <td>0</td>\n",
              "      <td>Tissue Plasminogen Activator</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>100 Years</td>\n",
              "      <td>Prisma Health-Midlands</td>\n",
              "      <td>Chest tubes are used for air or fluid removal ...</td>\n",
              "      <td>Inclusion Criteria: * Adult patients, age 18 y...</td>\n",
              "      <td>Chest tube removal</td>\n",
              "      <td>Fluid drainage | Need for other interventions ...</td>\n",
              "      <td>COMBINATION_PRODUCT:early tPA and DNase</td>\n",
              "      <td>387</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>95</th>\n",
              "      <td>NCT03906331</td>\n",
              "      <td>Expanded Access for the Treatment of Cancers W...</td>\n",
              "      <td>Expanded Access for the Treatment of Cancers W...</td>\n",
              "      <td>APPROVED_FOR_MARKETING</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>EXPANDED_ACCESS</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>Non Small Cell Lung Cancer, Medullary Thyroid ...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>Expanded access for participants with cancer w...</td>\n",
              "      <td>Inclusion Criteria: * Diagnosis of cancer with...</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>DRUG:Selpercatinib</td>\n",
              "      <td>836</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>96</th>\n",
              "      <td>NCT04731467</td>\n",
              "      <td>A Study of CM24 in Combination with Nivolumab ...</td>\n",
              "      <td>A Phase 1/2 Study to Assess the Safety, Tolera...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2021-03-19</td>\n",
              "      <td>2024-09-30</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1, PHASE2</td>\n",
              "      <td>79</td>\n",
              "      <td>Solid Tumor, Non Small Cell Lung Cancer, Pancr...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>Famewave Ltd.</td>\n",
              "      <td>This is an open-label, multicenter, multi-dose...</td>\n",
              "      <td>Inclusion Criteria: 1. Part A: Previously trea...</td>\n",
              "      <td>Part A: Incidence of treatment emergent advers...</td>\n",
              "      <td>Maximum serum concentration [Cmax] | Time of m...</td>\n",
              "      <td>DRUG:CM-24 and Nivolumab - Dose Escalation | D...</td>\n",
              "      <td>4302</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>NCT00241267</td>\n",
              "      <td>Bronchial Ultrasonography Via a Fibrescope: Pi...</td>\n",
              "      <td>Bronchial Ultrasonography Via a Fibrescope: Pi...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2005-03</td>\n",
              "      <td></td>\n",
              "      <td>OBSERVATIONAL</td>\n",
              "      <td></td>\n",
              "      <td>20</td>\n",
              "      <td>Pulmonary Neoplasms</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>University Hospital, Tours</td>\n",
              "      <td>The exploration of neoplastic pulmonary pathol...</td>\n",
              "      <td>Inclusion Criteria: * Assumed proximal neoplas...</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>DEVICE:Dedicated ultrasonographic probe during...</td>\n",
              "      <td>151</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>NCT03231111</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2017-07-25</td>\n",
              "      <td>2018-07-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NA</td>\n",
              "      <td>60</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>FEMALE</td>\n",
              "      <td>20 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>National Taiwan University Hospital</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients older than 20 ...</td>\n",
              "      <td>skindex-29</td>\n",
              "      <td></td>\n",
              "      <td>OTHER:Preventive Multimedia Teaching Program</td>\n",
              "      <td>469</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>NCT01392144</td>\n",
              "      <td>Phase II Evaluation of Exhaled Nitric Oxide (NO)</td>\n",
              "      <td>Phase II Evaluation of Exhaled Nitric Oxide as...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2011-08</td>\n",
              "      <td>2013-02</td>\n",
              "      <td>OBSERVATIONAL</td>\n",
              "      <td></td>\n",
              "      <td>36</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>M.D. Anderson Cancer Center</td>\n",
              "      <td>The goal of this clinical research study is to...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients will sign cons...</td>\n",
              "      <td>Ratio Between Weekly and Baseline Nitric Oxide...</td>\n",
              "      <td></td>\n",
              "      <td>PROCEDURE:Nitric oxide breath test | BEHAVIORA...</td>\n",
              "      <td>832</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>100 rows × 20 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-7210e363-3571-4aaf-81e6-9cc802ef1276')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-7210e363-3571-4aaf-81e6-9cc802ef1276 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-7210e363-3571-4aaf-81e6-9cc802ef1276');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-539b950b-9939-46cc-b6f0-eef88b9bf67b\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-539b950b-9939-46cc-b6f0-eef88b9bf67b')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-539b950b-9939-46cc-b6f0-eef88b9bf67b button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_0a0bcec7-b3cd-460f-b1d4-5dd80de244e0\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_0a0bcec7-b3cd-460f-b1d4-5dd80de244e0 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "         NCT_ID                                              Title  \\\n",
              "0   NCT03556228  Selective TrkA Inhibitor VMD-928 to Treat TrkA...   \n",
              "1   NCT00009971  Fenretinide in Treating Patients With Recurren...   \n",
              "2   NCT00260871  Genetic Epidemiological Study of Lung Cancer i...   \n",
              "3   NCT00721981  An Evaluation of the Clinical Treatment and Pa...   \n",
              "4   NCT03167281    Early Intrapleural TPA Instillation Versus Late   \n",
              "..          ...                                                ...   \n",
              "95  NCT03906331  Expanded Access for the Treatment of Cancers W...   \n",
              "96  NCT04731467  A Study of CM24 in Combination with Nivolumab ...   \n",
              "97  NCT00241267  Bronchial Ultrasonography Via a Fibrescope: Pi...   \n",
              "98  NCT03231111  The Effectiveness of Using Preventive Multimed...   \n",
              "99  NCT01392144   Phase II Evaluation of Exhaled Nitric Oxide (NO)   \n",
              "\n",
              "                                       Official_Title                  Status  \\\n",
              "0   An Open-Label, Multiple-Dose, Dose-Escalation ...              RECRUITING   \n",
              "1   Phase II Trial Of Fenretinide (NSC-374551; IND...               COMPLETED   \n",
              "2   Genetic Epidemiological Study of Lung Cancer i...                 UNKNOWN   \n",
              "3   A Non-interventional Study for Evaluation of t...              TERMINATED   \n",
              "4     Early Intrapleural TPA Instillation Versus Late               WITHDRAWN   \n",
              "..                                                ...                     ...   \n",
              "95  Expanded Access for the Treatment of Cancers W...  APPROVED_FOR_MARKETING   \n",
              "96  A Phase 1/2 Study to Assess the Safety, Tolera...               COMPLETED   \n",
              "97  Bronchial Ultrasonography Via a Fibrescope: Pi...              TERMINATED   \n",
              "98  The Effectiveness of Using Preventive Multimed...                 UNKNOWN   \n",
              "99  Phase II Evaluation of Exhaled Nitric Oxide as...               COMPLETED   \n",
              "\n",
              "    Start_Date Primary_Completion       Study_Type          Phases Enrollment  \\\n",
              "0   2018-06-08            2026-12   INTERVENTIONAL          PHASE1         82   \n",
              "1      2000-11            2005-09   INTERVENTIONAL          PHASE2         32   \n",
              "2      2002-05                       OBSERVATIONAL                       1500   \n",
              "3      2009-04                       OBSERVATIONAL                        120   \n",
              "4   2017-02-17         2021-03-10   INTERVENTIONAL          PHASE4          0   \n",
              "..         ...                ...              ...             ...        ...   \n",
              "95                                 EXPANDED_ACCESS                              \n",
              "96  2021-03-19         2024-09-30   INTERVENTIONAL  PHASE1, PHASE2         79   \n",
              "97     2005-03                       OBSERVATIONAL                         20   \n",
              "98  2017-07-25         2018-07-01   INTERVENTIONAL              NA         60   \n",
              "99     2011-08            2013-02    OBSERVATIONAL                         36   \n",
              "\n",
              "                                           Conditions     Sex   Min_Age  \\\n",
              "0   Head and Neck Carcinoma, Adenoid Cystic Carcin...     ALL  18 Years   \n",
              "1                                         Lung Cancer     ALL  18 Years   \n",
              "2                                         Lung Cancer     ALL             \n",
              "3             Lung Cancer, Non-small Cell Lung Cancer     ALL  18 Years   \n",
              "4                        Tissue Plasminogen Activator     ALL  18 Years   \n",
              "..                                                ...     ...       ...   \n",
              "95  Non Small Cell Lung Cancer, Medullary Thyroid ...     ALL  18 Years   \n",
              "96  Solid Tumor, Non Small Cell Lung Cancer, Pancr...     ALL  18 Years   \n",
              "97                                Pulmonary Neoplasms     ALL  18 Years   \n",
              "98                                        Lung Cancer  FEMALE  20 Years   \n",
              "99                                        Lung Cancer     ALL  18 Years   \n",
              "\n",
              "      Max_Age                                 Lead_Sponsor  \\\n",
              "0    80 Years                             VM Oncology, LLC   \n",
              "1                          National Cancer Institute (NCI)   \n",
              "2              National Health Research Institutes, Taiwan   \n",
              "3                                              AstraZeneca   \n",
              "4   100 Years                       Prisma Health-Midlands   \n",
              "..        ...                                          ...   \n",
              "95                                   Eli Lilly and Company   \n",
              "96                                           Famewave Ltd.   \n",
              "97                              University Hospital, Tours   \n",
              "98   80 Years          National Taiwan University Hospital   \n",
              "99                             M.D. Anderson Cancer Center   \n",
              "\n",
              "                                        Brief_Summary  \\\n",
              "0   This is a multicenter, open-label, Phase 1 stu...   \n",
              "1   Phase II trial to study the effectiveness of f...   \n",
              "2   Lung adenocarcinoma in Chinese females is hypo...   \n",
              "3   The main purpose of this study is the identifi...   \n",
              "4   Chest tubes are used for air or fluid removal ...   \n",
              "..                                                ...   \n",
              "95  Expanded access for participants with cancer w...   \n",
              "96  This is an open-label, multicenter, multi-dose...   \n",
              "97  The exploration of neoplastic pulmonary pathol...   \n",
              "98  The Effectiveness of Using Preventive Multimed...   \n",
              "99  The goal of this clinical research study is to...   \n",
              "\n",
              "                                          Eligibility  \\\n",
              "0   Key Inclusion Criteria: * Histologically or cy...   \n",
              "1   DISEASE CHARACTERISTICS: * Histologically or c...   \n",
              "2   Inclusion Criteria: * lung adenocarcinoma Excl...   \n",
              "3   Inclusion Criteria: * Patients suffering from ...   \n",
              "4   Inclusion Criteria: * Adult patients, age 18 y...   \n",
              "..                                                ...   \n",
              "95  Inclusion Criteria: * Diagnosis of cancer with...   \n",
              "96  Inclusion Criteria: 1. Part A: Previously trea...   \n",
              "97  Inclusion Criteria: * Assumed proximal neoplas...   \n",
              "98  Inclusion Criteria: 1. Patients older than 20 ...   \n",
              "99  Inclusion Criteria: 1. Patients will sign cons...   \n",
              "\n",
              "                                     Primary_Measures  \\\n",
              "0   Number and severity of treatment-emergent Adve...   \n",
              "1                                                       \n",
              "2                                                       \n",
              "3   To obtain patient preferences in direct correl...   \n",
              "4                                  Chest tube removal   \n",
              "..                                                ...   \n",
              "95                                                      \n",
              "96  Part A: Incidence of treatment emergent advers...   \n",
              "97                                                      \n",
              "98                                         skindex-29   \n",
              "99  Ratio Between Weekly and Baseline Nitric Oxide...   \n",
              "\n",
              "                                   Secondary_Measures  \\\n",
              "0   Area under the plasma concentration versus tim...   \n",
              "1                                                       \n",
              "2                                                       \n",
              "3   current medical practice treatment objectives ...   \n",
              "4   Fluid drainage | Need for other interventions ...   \n",
              "..                                                ...   \n",
              "95                                                      \n",
              "96  Maximum serum concentration [Cmax] | Time of m...   \n",
              "97                                                      \n",
              "98                                                      \n",
              "99                                                      \n",
              "\n",
              "                                        Interventions  elig_len  \n",
              "0   DRUG:VMD-928 300 mg Tablet (ongoing); 100 mg C...      4124  \n",
              "1                                    DRUG:fenretinide      1815  \n",
              "2                                                            64  \n",
              "3                                                           646  \n",
              "4             COMBINATION_PRODUCT:early tPA and DNase       387  \n",
              "..                                                ...       ...  \n",
              "95                                 DRUG:Selpercatinib       836  \n",
              "96  DRUG:CM-24 and Nivolumab - Dose Escalation | D...      4302  \n",
              "97  DEVICE:Dedicated ultrasonographic probe during...       151  \n",
              "98       OTHER:Preventive Multimedia Teaching Program       469  \n",
              "99  PROCEDURE:Nitric oxide breath test | BEHAVIORA...       832  \n",
              "\n",
              "[100 rows x 20 columns]"
            ]
          },
          "execution_count": 7,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {
        "id": "SMVPNcoslIUi"
      },
      "outputs": [],
      "source": [
        "def is_systemic_anticancer_trial(row):\n",
        "    text = \" \".join([\n",
        "        str(row.get('Title', '')),\n",
        "        str(row.get('Official_Title', '')),\n",
        "        str(row.get('Brief_Summary', '')),\n",
        "        str(row.get('Eligibility', '')),\n",
        "        str(row.get('Conditions', '')),\n",
        "        str(row.get('Interventions', ''))\n",
        "    ]).lower()\n",
        "\n",
        "    # 1. HARD EXCLUDE — non-drug / procedural / local therapy (kill 99% of false positives instantly)\n",
        "    junk_keywords = [\n",
        "        # Locoregional / ablation / device\n",
        "        \"hifu\", \"radiofrequency ablation\", \"rfa\", \"cryoablation\", \"microwave ablation\",\n",
        "        \"tace\", \"deb-tace\", \"y90\", \"radioembolization\", \"sir-spheres\", \"therasphere\",\n",
        "        \"hepatic arterial\", \"haic\", \"chemoembolization\", \"embolization\",\n",
        "        \"sbrt\", \"cyberknife\", \"gamma knife\", \"stereotactic body\", \"stereotactic radiosurgery\",\n",
        "        \"brachytherapy\", \"hdr \", \"intrathecal\", \"lumbar puncture\", \"pleurodesis\",\n",
        "        \"thoracentesis\", \"paracentesis\", \"pleural catheter\", \"chest tube\", \"pleurx\",\n",
        "\n",
        "        # Surgical / diagnostic procedures\n",
        "        \"surgery\", \"resection\", \"lobectomy\", \"wedge resection\", \"thoracoscopic\", \"vats\", \"ivats\",\n",
        "        \"biopsy only\", \"diagnostic biopsy\", \"tissue collection\",\n",
        "\n",
        "        # Prevention / screening / supportive care\n",
        "        \"prevention\", \"chemoprevention\", \"smoking cessation\", \"aspirin\", \"statin\",\n",
        "        \"screening\", \"early detection\", \"surveillance\",\n",
        "\n",
        "        # Non-cancer or minimal anticancer intent\n",
        "        \"supportive care\", \"palliative care only\", \"best supportive care\", \"placebo\",\n",
        "        \"radiation only\", \"radiotherapy alone\", \"radiation therapy as single modality\",\n",
        "\n",
        "        # Others\n",
        "        \"stage iiia\", \"stage iii\", \"inoperable locally advanced\", \"concurrent chemoradiation\", \"definitive chemoradiation\",\n",
        "        \"induction chemotherapy.*allowed\", \"no study drug\", \"radiation therapy.*primary\", \"thoracic radiation\"\n",
        "    ]\n",
        "    if any(kw in text for kw in junk_keywords):\n",
        "        return False\n",
        "\n",
        "    # 2. Must have at least ONE real anticancer drug keyword\n",
        "    drug_keywords = [\n",
        "        \"chemotherapy\", \"targeted therapy\", \"immunotherapy\", \"pd-1\", \"pd-l1\", \"ctla-4\",\n",
        "        \"parp inhibitor\", \"tkis\", \"egfr\", \"alk \", \"braf\", \"mek\", \"mtor\", \"pi3k\",\n",
        "        \"cdk4/6\", \"bcl-2\", \"antibody-drug conjugate\", \"adc\", \"bispecific\",\n",
        "        \"car-t\", \"tcr-t\", \"til therapy\", \"vaccine\", # (vaccine often therapeutic in oncology)\n",
        "        \"olaparib\", \"osimertinib\", \"pembrolizumab\", \"nivolumab\", \"atezolizumab\",\n",
        "        \"bevacizumab\", \"trastuzumab\", \"cetuximab\", \"ramucirumab\", \"everolimus\",\n",
        "        \"lenvatinib\", \"sunitinib\", \"pazopanib\", \"cabozantinib\", \"regorafenib\"\n",
        "    ]\n",
        "    if not any(kw in text for kw in drug_keywords):\n",
        "        return False\n",
        "\n",
        "    # 3. Final safety net: must contain at least one of these strong signals\n",
        "    strong_signals = [\n",
        "        \"phase 1\", \"phase i\", \"phase 2\", \"phase ii\", \"phase 3\", \"phase iii\",\n",
        "        \"dose escalation\", \"maximum tolerated dose\", \"recommended phase 2 dose\",\n",
        "        \"progression-free survival\", \"overall survival\", \"objective response rate\",\n",
        "        \"recist\", \"irrc\", \"pfs\", \"os\", \"orr\", \"dcr\"\n",
        "    ]\n",
        "    if not any(signal in text for signal in strong_signals):\n",
        "        return False\n",
        "\n",
        "    return True\n",
        "\n",
        "\n",
        "# Apply it\n",
        "df = df[\n",
        "    (df['Study_Type'] == 'INTERVENTIONAL') &\n",
        "    df.apply(is_systemic_anticancer_trial, axis=1)\n",
        "].copy()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 688
        },
        "id": "o-QIdG5PGMBU",
        "outputId": "3026a9c8-9d92-4487-a502-c36e7d454d57"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "repr_error": "0",
              "type": "dataframe",
              "variable_name": "df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-a37a02cd-b13c-4f5f-bd25-3506a072cc49\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Official_Title</th>\n",
              "      <th>Status</th>\n",
              "      <th>Start_Date</th>\n",
              "      <th>Primary_Completion</th>\n",
              "      <th>Study_Type</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Min_Age</th>\n",
              "      <th>Max_Age</th>\n",
              "      <th>Lead_Sponsor</th>\n",
              "      <th>Brief_Summary</th>\n",
              "      <th>Eligibility</th>\n",
              "      <th>Primary_Measures</th>\n",
              "      <th>Secondary_Measures</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>elig_len</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT00009971</td>\n",
              "      <td>Fenretinide in Treating Patients With Recurren...</td>\n",
              "      <td>Phase II Trial Of Fenretinide (NSC-374551; IND...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2000-11</td>\n",
              "      <td>2005-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>32</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Phase II trial to study the effectiveness of f...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or c...</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>DRUG:fenretinide</td>\n",
              "      <td>1815</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>NCT03836352</td>\n",
              "      <td>Study of an Immunotherapeutic, DPX-Survivac, i...</td>\n",
              "      <td>A Phase 2, Open-label, Multicenter, Study of a...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2018-12-21</td>\n",
              "      <td>2023-12-31</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>184</td>\n",
              "      <td>Ovarian Cancer, Hepatocellular Carcinoma, Non-...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>ImmunoVaccine Technologies, Inc. (IMV Inc.)</td>\n",
              "      <td>This study will assess the safety and efficacy...</td>\n",
              "      <td>Key Inclusion Criteria: * Subjects with advanc...</td>\n",
              "      <td>Efficacy as measured by objective response rat...</td>\n",
              "      <td>Objective response rate | Duration of response...</td>\n",
              "      <td>OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...</td>\n",
              "      <td>2335</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>NCT01249443</td>\n",
              "      <td>Paclitaxel and Carboplatin in Treating Patient...</td>\n",
              "      <td>A Phase 1 Study of Paclitaxel and Carboplatin ...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2013-11</td>\n",
              "      <td>2016-05</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>17</td>\n",
              "      <td>HIV Infection, Recurrent Anal Cancer, Recurren...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>AIDS Malignancy Consortium</td>\n",
              "      <td>This phase I clinical trial is studying the si...</td>\n",
              "      <td>Inclusion Criteria: * Patients must have known...</td>\n",
              "      <td>Incidence of adverse events during paclitaxel ...</td>\n",
              "      <td>Response rates in patients with lung, head and...</td>\n",
              "      <td>DRUG:vorinostat | OTHER:diagnostic laboratory ...</td>\n",
              "      <td>8612</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50</th>\n",
              "      <td>NCT04421352</td>\n",
              "      <td>Safety and Tolerability Evaluation of Low-dose...</td>\n",
              "      <td>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2021-01-12</td>\n",
              "      <td>2023-12-22</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>11</td>\n",
              "      <td>Relapsed Small Cell Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>CStone Pharmaceuticals</td>\n",
              "      <td>A Phase Ia/Ib Safety and Tolerability Evaluati...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients with histologi...</td>\n",
              "      <td>To determine the recommended radiation dose an...</td>\n",
              "      <td>Incidence of Adverse Events (AE) and Dose-Limi...</td>\n",
              "      <td>DRUG:CS1001</td>\n",
              "      <td>1904</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>62</th>\n",
              "      <td>NCT01774526</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2010-12</td>\n",
              "      <td>2016-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NA</td>\n",
              "      <td>40</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>21 Years</td>\n",
              "      <td></td>\n",
              "      <td>National University Hospital, Singapore</td>\n",
              "      <td>Lung Cancer continues to be the major cause of...</td>\n",
              "      <td>Inclusion Criteria: * Asian ethnicity * Age \\&gt;...</td>\n",
              "      <td>Descriptive study of our patients with lung ad...</td>\n",
              "      <td></td>\n",
              "      <td>OTHER:Characterise the molecular epidemiology ...</td>\n",
              "      <td>535</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>72</th>\n",
              "      <td>NCT01780675</td>\n",
              "      <td>Hippocampus Avoidance PCI vs PCI</td>\n",
              "      <td>Prophylactic Cranial Irradiation With or Witho...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-04</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>168</td>\n",
              "      <td>Small Cell Lung Cancer, Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>The Netherlands Cancer Institute</td>\n",
              "      <td>Using Intensity Modulated radiotherapy it is p...</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cance...</td>\n",
              "      <td>neurocognitive decline</td>\n",
              "      <td>safety</td>\n",
              "      <td>RADIATION:Radiation Prophylactic Cranial Irrad...</td>\n",
              "      <td>741</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>NCT03231111</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2017-07-25</td>\n",
              "      <td>2018-07-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NA</td>\n",
              "      <td>60</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>FEMALE</td>\n",
              "      <td>20 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>National Taiwan University Hospital</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients older than 20 ...</td>\n",
              "      <td>skindex-29</td>\n",
              "      <td></td>\n",
              "      <td>OTHER:Preventive Multimedia Teaching Program</td>\n",
              "      <td>469</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-a37a02cd-b13c-4f5f-bd25-3506a072cc49')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-a37a02cd-b13c-4f5f-bd25-3506a072cc49 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-a37a02cd-b13c-4f5f-bd25-3506a072cc49');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-78437ef4-2406-4a0d-a86f-9e709dc57e47\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-78437ef4-2406-4a0d-a86f-9e709dc57e47')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-78437ef4-2406-4a0d-a86f-9e709dc57e47 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_6c1c87b3-6ddf-46a1-9fc9-a2cff56de181\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_6c1c87b3-6ddf-46a1-9fc9-a2cff56de181 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "         NCT_ID                                              Title  \\\n",
              "1   NCT00009971  Fenretinide in Treating Patients With Recurren...   \n",
              "18  NCT03836352  Study of an Immunotherapeutic, DPX-Survivac, i...   \n",
              "34  NCT01249443  Paclitaxel and Carboplatin in Treating Patient...   \n",
              "50  NCT04421352  Safety and Tolerability Evaluation of Low-dose...   \n",
              "62  NCT01774526  Molecular Epidemiology of Lung Adenocarcinoma ...   \n",
              "72  NCT01780675                   Hippocampus Avoidance PCI vs PCI   \n",
              "98  NCT03231111  The Effectiveness of Using Preventive Multimed...   \n",
              "\n",
              "                                       Official_Title                 Status  \\\n",
              "1   Phase II Trial Of Fenretinide (NSC-374551; IND...              COMPLETED   \n",
              "18  A Phase 2, Open-label, Multicenter, Study of a...  ACTIVE_NOT_RECRUITING   \n",
              "34  A Phase 1 Study of Paclitaxel and Carboplatin ...             TERMINATED   \n",
              "50  A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...              COMPLETED   \n",
              "62  Molecular Epidemiology of Lung Adenocarcinoma ...                UNKNOWN   \n",
              "72  Prophylactic Cranial Irradiation With or Witho...              COMPLETED   \n",
              "98  The Effectiveness of Using Preventive Multimed...                UNKNOWN   \n",
              "\n",
              "    Start_Date Primary_Completion      Study_Type  Phases Enrollment  \\\n",
              "1      2000-11            2005-09  INTERVENTIONAL  PHASE2         32   \n",
              "18  2018-12-21         2023-12-31  INTERVENTIONAL  PHASE2        184   \n",
              "34     2013-11            2016-05  INTERVENTIONAL  PHASE1         17   \n",
              "50  2021-01-12         2023-12-22  INTERVENTIONAL  PHASE1         11   \n",
              "62     2010-12            2016-12  INTERVENTIONAL      NA         40   \n",
              "72     2013-04         2019-04-01  INTERVENTIONAL  PHASE3        168   \n",
              "98  2017-07-25         2018-07-01  INTERVENTIONAL      NA         60   \n",
              "\n",
              "                                           Conditions     Sex   Min_Age  \\\n",
              "1                                         Lung Cancer     ALL  18 Years   \n",
              "18  Ovarian Cancer, Hepatocellular Carcinoma, Non-...     ALL  18 Years   \n",
              "34  HIV Infection, Recurrent Anal Cancer, Recurren...     ALL  18 Years   \n",
              "50                    Relapsed Small Cell Lung Cancer     ALL  18 Years   \n",
              "62                                        Lung Cancer     ALL  21 Years   \n",
              "72                Small Cell Lung Cancer, Lung Cancer     ALL  18 Years   \n",
              "98                                        Lung Cancer  FEMALE  20 Years   \n",
              "\n",
              "     Max_Age                                 Lead_Sponsor  \\\n",
              "1                         National Cancer Institute (NCI)   \n",
              "18            ImmunoVaccine Technologies, Inc. (IMV Inc.)   \n",
              "34                             AIDS Malignancy Consortium   \n",
              "50  75 Years                       CStone Pharmaceuticals   \n",
              "62                National University Hospital, Singapore   \n",
              "72                       The Netherlands Cancer Institute   \n",
              "98  80 Years          National Taiwan University Hospital   \n",
              "\n",
              "                                        Brief_Summary  \\\n",
              "1   Phase II trial to study the effectiveness of f...   \n",
              "18  This study will assess the safety and efficacy...   \n",
              "34  This phase I clinical trial is studying the si...   \n",
              "50  A Phase Ia/Ib Safety and Tolerability Evaluati...   \n",
              "62  Lung Cancer continues to be the major cause of...   \n",
              "72  Using Intensity Modulated radiotherapy it is p...   \n",
              "98  The Effectiveness of Using Preventive Multimed...   \n",
              "\n",
              "                                          Eligibility  \\\n",
              "1   DISEASE CHARACTERISTICS: * Histologically or c...   \n",
              "18  Key Inclusion Criteria: * Subjects with advanc...   \n",
              "34  Inclusion Criteria: * Patients must have known...   \n",
              "50  Inclusion Criteria: 1. Patients with histologi...   \n",
              "62  Inclusion Criteria: * Asian ethnicity * Age \\>...   \n",
              "72  Inclusion Criteria: * \\- Small Cell Lung Cance...   \n",
              "98  Inclusion Criteria: 1. Patients older than 20 ...   \n",
              "\n",
              "                                     Primary_Measures  \\\n",
              "1                                                       \n",
              "18  Efficacy as measured by objective response rat...   \n",
              "34  Incidence of adverse events during paclitaxel ...   \n",
              "50  To determine the recommended radiation dose an...   \n",
              "62  Descriptive study of our patients with lung ad...   \n",
              "72                             neurocognitive decline   \n",
              "98                                         skindex-29   \n",
              "\n",
              "                                   Secondary_Measures  \\\n",
              "1                                                       \n",
              "18  Objective response rate | Duration of response...   \n",
              "34  Response rates in patients with lung, head and...   \n",
              "50  Incidence of Adverse Events (AE) and Dose-Limi...   \n",
              "62                                                      \n",
              "72                                             safety   \n",
              "98                                                      \n",
              "\n",
              "                                        Interventions  elig_len  \n",
              "1                                    DRUG:fenretinide      1815  \n",
              "18  OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...      2335  \n",
              "34  DRUG:vorinostat | OTHER:diagnostic laboratory ...      8612  \n",
              "50                                        DRUG:CS1001      1904  \n",
              "62  OTHER:Characterise the molecular epidemiology ...       535  \n",
              "72  RADIATION:Radiation Prophylactic Cranial Irrad...       741  \n",
              "98       OTHER:Preventive Multimedia Teaching Program       469  "
            ]
          },
          "execution_count": 9,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Rpn8mNDKnKpN",
        "outputId": "3aa1384d-09bd-4a4f-cc46-09210cda78e8"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "After filtering, only 6 rows remain (≤100), keeping all.\n"
          ]
        }
      ],
      "source": [
        "\n",
        "# Step 1: Keep only rows where elig_len <= 3500\n",
        "df_filtered = df[(df['elig_len'] <= 3500) & (df['elig_len'] >= 300)].copy()\n",
        "\n",
        "# Step 2: If still more than 100 rows → randomly sample 100 (reproducible if you set seed)\n",
        "if len(df_filtered) > 100:\n",
        "    df_filtered = df_filtered.sample(n=100, random_state=2)   # remove random_state if you want true random each time\n",
        "else:\n",
        "    print(f\"After filtering, only {len(df_filtered)} rows remain (≤100), keeping all.\")\n",
        "\n",
        "# Reset index if you want clean numbering\n",
        "df = df_filtered.reset_index(drop=True)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 11,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 604
        },
        "id": "ufZ-V3VJnMEN",
        "outputId": "4c28c178-62c8-4cf8-d837-0c9a6260d692"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 6,\n  \"fields\": [\n    {\n      \"column\": \"NCT_ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"NCT00009971\",\n          \"NCT03836352\",\n          \"NCT03231111\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer\",\n          \"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors\",\n          \"The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Official_Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer\",\n          \"A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.\",\n          \"The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Status\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"COMPLETED\",\n          \"ACTIVE_NOT_RECRUITING\",\n          \"UNKNOWN\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Start_Date\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"2000-11\",\n          \"2018-12-21\",\n          \"2017-07-25\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_Completion\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"2005-09\",\n          \"2023-12-31\",\n          \"2018-07-01\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study_Type\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"INTERVENTIONAL\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"PHASE1\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": 11,\n        \"max\": 184,\n        \"num_unique_values\": 6,\n        \"samples\": [\n          32\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"FEMALE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Min_Age\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"18 Years\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Max_Age\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Lead_Sponsor\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"National Cancer Institute (NCI)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Brief_Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Eligibility\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) after platinum-containing chemotherapy regimen with or without thoracic radiotherapy * Limited stage or extensive stage SCLC * Measurable disease * At least 20 mm by conventional techniques OR * At least 10 mm with spiral CT scan * No pleural effusions, bone metastases, brain metastases, or abnormal radionucleotide scans as sole evidence of disease * No symptomatic or uncontrolled brain or leptomeningeal disease * Previously treated brain metastases allowed if neurologically stable PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-2 Hematopoietic: * WBC at least 2,500/mm\\\\^3 * Platelet count at least 70,000/mm\\\\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No symptomatic heart disease * No myocardial infarction within the past 6 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 1 month before, during, and for 2 months after study * No pre-existing retinal degenerative disease (e.g., retinitis pigmentosa or associated disorders) * No other serious concurrent illness * No other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ PRIOR CONCURRENT THERAPY: Chemotherapy: * At least 3 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens Endocrine therapy: * Concurrent steroids allowed at stable dose Radiotherapy: * No prior radiotherapy to study lesions Other: * At least 3 weeks since prior systemic retinoid or carotenoid therapy * No concurrent anticonvulsants\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary_Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary_Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"Objective response rate | Duration of response | Disease control rate | Progression Free Survival | Overall survival\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Interventions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"DRUG:fenretinide\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"elig_len\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 811,\n        \"min\": 469,\n        \"max\": 2335,\n        \"num_unique_values\": 6,\n        \"samples\": [\n          1815\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-3c871d20-958c-487d-ab0a-ac5fe50278f4\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Official_Title</th>\n",
              "      <th>Status</th>\n",
              "      <th>Start_Date</th>\n",
              "      <th>Primary_Completion</th>\n",
              "      <th>Study_Type</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Min_Age</th>\n",
              "      <th>Max_Age</th>\n",
              "      <th>Lead_Sponsor</th>\n",
              "      <th>Brief_Summary</th>\n",
              "      <th>Eligibility</th>\n",
              "      <th>Primary_Measures</th>\n",
              "      <th>Secondary_Measures</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>elig_len</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00009971</td>\n",
              "      <td>Fenretinide in Treating Patients With Recurren...</td>\n",
              "      <td>Phase II Trial Of Fenretinide (NSC-374551; IND...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2000-11</td>\n",
              "      <td>2005-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>32</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Phase II trial to study the effectiveness of f...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or c...</td>\n",
              "      <td></td>\n",
              "      <td></td>\n",
              "      <td>DRUG:fenretinide</td>\n",
              "      <td>1815</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT03836352</td>\n",
              "      <td>Study of an Immunotherapeutic, DPX-Survivac, i...</td>\n",
              "      <td>A Phase 2, Open-label, Multicenter, Study of a...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2018-12-21</td>\n",
              "      <td>2023-12-31</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>184</td>\n",
              "      <td>Ovarian Cancer, Hepatocellular Carcinoma, Non-...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>ImmunoVaccine Technologies, Inc. (IMV Inc.)</td>\n",
              "      <td>This study will assess the safety and efficacy...</td>\n",
              "      <td>Key Inclusion Criteria: * Subjects with advanc...</td>\n",
              "      <td>Efficacy as measured by objective response rat...</td>\n",
              "      <td>Objective response rate | Duration of response...</td>\n",
              "      <td>OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...</td>\n",
              "      <td>2335</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT04421352</td>\n",
              "      <td>Safety and Tolerability Evaluation of Low-dose...</td>\n",
              "      <td>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2021-01-12</td>\n",
              "      <td>2023-12-22</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>11</td>\n",
              "      <td>Relapsed Small Cell Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>CStone Pharmaceuticals</td>\n",
              "      <td>A Phase Ia/Ib Safety and Tolerability Evaluati...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients with histologi...</td>\n",
              "      <td>To determine the recommended radiation dose an...</td>\n",
              "      <td>Incidence of Adverse Events (AE) and Dose-Limi...</td>\n",
              "      <td>DRUG:CS1001</td>\n",
              "      <td>1904</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT01774526</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2010-12</td>\n",
              "      <td>2016-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NA</td>\n",
              "      <td>40</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>21 Years</td>\n",
              "      <td></td>\n",
              "      <td>National University Hospital, Singapore</td>\n",
              "      <td>Lung Cancer continues to be the major cause of...</td>\n",
              "      <td>Inclusion Criteria: * Asian ethnicity * Age \\&gt;...</td>\n",
              "      <td>Descriptive study of our patients with lung ad...</td>\n",
              "      <td></td>\n",
              "      <td>OTHER:Characterise the molecular epidemiology ...</td>\n",
              "      <td>535</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT01780675</td>\n",
              "      <td>Hippocampus Avoidance PCI vs PCI</td>\n",
              "      <td>Prophylactic Cranial Irradiation With or Witho...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-04</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>168</td>\n",
              "      <td>Small Cell Lung Cancer, Lung Cancer</td>\n",
              "      <td>ALL</td>\n",
              "      <td>18 Years</td>\n",
              "      <td></td>\n",
              "      <td>The Netherlands Cancer Institute</td>\n",
              "      <td>Using Intensity Modulated radiotherapy it is p...</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cance...</td>\n",
              "      <td>neurocognitive decline</td>\n",
              "      <td>safety</td>\n",
              "      <td>RADIATION:Radiation Prophylactic Cranial Irrad...</td>\n",
              "      <td>741</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>NCT03231111</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2017-07-25</td>\n",
              "      <td>2018-07-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NA</td>\n",
              "      <td>60</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>FEMALE</td>\n",
              "      <td>20 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>National Taiwan University Hospital</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients older than 20 ...</td>\n",
              "      <td>skindex-29</td>\n",
              "      <td></td>\n",
              "      <td>OTHER:Preventive Multimedia Teaching Program</td>\n",
              "      <td>469</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-3c871d20-958c-487d-ab0a-ac5fe50278f4')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-3c871d20-958c-487d-ab0a-ac5fe50278f4 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-3c871d20-958c-487d-ab0a-ac5fe50278f4');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-efad69e6-af82-4ba5-a769-739c818ab4fc\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-efad69e6-af82-4ba5-a769-739c818ab4fc')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-efad69e6-af82-4ba5-a769-739c818ab4fc button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_127c8cdb-9f2b-4eb6-88a5-abed8e179d56\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_127c8cdb-9f2b-4eb6-88a5-abed8e179d56 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "        NCT_ID                                              Title  \\\n",
              "0  NCT00009971  Fenretinide in Treating Patients With Recurren...   \n",
              "1  NCT03836352  Study of an Immunotherapeutic, DPX-Survivac, i...   \n",
              "2  NCT04421352  Safety and Tolerability Evaluation of Low-dose...   \n",
              "3  NCT01774526  Molecular Epidemiology of Lung Adenocarcinoma ...   \n",
              "4  NCT01780675                   Hippocampus Avoidance PCI vs PCI   \n",
              "5  NCT03231111  The Effectiveness of Using Preventive Multimed...   \n",
              "\n",
              "                                      Official_Title                 Status  \\\n",
              "0  Phase II Trial Of Fenretinide (NSC-374551; IND...              COMPLETED   \n",
              "1  A Phase 2, Open-label, Multicenter, Study of a...  ACTIVE_NOT_RECRUITING   \n",
              "2  A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...              COMPLETED   \n",
              "3  Molecular Epidemiology of Lung Adenocarcinoma ...                UNKNOWN   \n",
              "4  Prophylactic Cranial Irradiation With or Witho...              COMPLETED   \n",
              "5  The Effectiveness of Using Preventive Multimed...                UNKNOWN   \n",
              "\n",
              "   Start_Date Primary_Completion      Study_Type  Phases Enrollment  \\\n",
              "0     2000-11            2005-09  INTERVENTIONAL  PHASE2         32   \n",
              "1  2018-12-21         2023-12-31  INTERVENTIONAL  PHASE2        184   \n",
              "2  2021-01-12         2023-12-22  INTERVENTIONAL  PHASE1         11   \n",
              "3     2010-12            2016-12  INTERVENTIONAL      NA         40   \n",
              "4     2013-04         2019-04-01  INTERVENTIONAL  PHASE3        168   \n",
              "5  2017-07-25         2018-07-01  INTERVENTIONAL      NA         60   \n",
              "\n",
              "                                          Conditions     Sex   Min_Age  \\\n",
              "0                                        Lung Cancer     ALL  18 Years   \n",
              "1  Ovarian Cancer, Hepatocellular Carcinoma, Non-...     ALL  18 Years   \n",
              "2                    Relapsed Small Cell Lung Cancer     ALL  18 Years   \n",
              "3                                        Lung Cancer     ALL  21 Years   \n",
              "4                Small Cell Lung Cancer, Lung Cancer     ALL  18 Years   \n",
              "5                                        Lung Cancer  FEMALE  20 Years   \n",
              "\n",
              "    Max_Age                                 Lead_Sponsor  \\\n",
              "0                        National Cancer Institute (NCI)   \n",
              "1            ImmunoVaccine Technologies, Inc. (IMV Inc.)   \n",
              "2  75 Years                       CStone Pharmaceuticals   \n",
              "3                National University Hospital, Singapore   \n",
              "4                       The Netherlands Cancer Institute   \n",
              "5  80 Years          National Taiwan University Hospital   \n",
              "\n",
              "                                       Brief_Summary  \\\n",
              "0  Phase II trial to study the effectiveness of f...   \n",
              "1  This study will assess the safety and efficacy...   \n",
              "2  A Phase Ia/Ib Safety and Tolerability Evaluati...   \n",
              "3  Lung Cancer continues to be the major cause of...   \n",
              "4  Using Intensity Modulated radiotherapy it is p...   \n",
              "5  The Effectiveness of Using Preventive Multimed...   \n",
              "\n",
              "                                         Eligibility  \\\n",
              "0  DISEASE CHARACTERISTICS: * Histologically or c...   \n",
              "1  Key Inclusion Criteria: * Subjects with advanc...   \n",
              "2  Inclusion Criteria: 1. Patients with histologi...   \n",
              "3  Inclusion Criteria: * Asian ethnicity * Age \\>...   \n",
              "4  Inclusion Criteria: * \\- Small Cell Lung Cance...   \n",
              "5  Inclusion Criteria: 1. Patients older than 20 ...   \n",
              "\n",
              "                                    Primary_Measures  \\\n",
              "0                                                      \n",
              "1  Efficacy as measured by objective response rat...   \n",
              "2  To determine the recommended radiation dose an...   \n",
              "3  Descriptive study of our patients with lung ad...   \n",
              "4                             neurocognitive decline   \n",
              "5                                         skindex-29   \n",
              "\n",
              "                                  Secondary_Measures  \\\n",
              "0                                                      \n",
              "1  Objective response rate | Duration of response...   \n",
              "2  Incidence of Adverse Events (AE) and Dose-Limi...   \n",
              "3                                                      \n",
              "4                                             safety   \n",
              "5                                                      \n",
              "\n",
              "                                       Interventions  elig_len  \n",
              "0                                   DRUG:fenretinide      1815  \n",
              "1  OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...      2335  \n",
              "2                                        DRUG:CS1001      1904  \n",
              "3  OTHER:Characterise the molecular epidemiology ...       535  \n",
              "4  RADIATION:Radiation Prophylactic Cranial Irrad...       741  \n",
              "5       OTHER:Preventive Multimedia Teaching Program       469  "
            ]
          },
          "execution_count": 11,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "cgmdQyC3nO_m"
      },
      "outputs": [],
      "source": [
        "# ============= Save initial cleaned CSV ============\n",
        "out_csv = f\"trials_clean_N{len(df)}.csv\"\n",
        "df.to_csv(out_csv, index=False)\n",
        "print(\"Saved:\", out_csv)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "xA8b4wL2nRc_"
      },
      "outputs": [],
      "source": [
        "df = pd.read_csv(out_csv)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "p4Q0neJSnVCX",
        "outputId": "807f3caa-19b6-4b9e-a369-1a37271fb0f9"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Get your free key at https://console.groq.com/keys → ··········\n"
          ]
        }
      ],
      "source": [
        "from groq import Groq\n",
        "from getpass import getpass\n",
        "\n",
        "\n",
        "GROQ_API_KEY = getpass(\"Get your free key at https://console.groq.com/keys → \")\n",
        "\n",
        "client = Groq(api_key=GROQ_API_KEY)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "qfoSseOvtfsw"
      },
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "metadata": {
        "id": "g7k3PGgKt14L"
      },
      "outputs": [],
      "source": [
        "df_1 = df.copy()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "metadata": {
        "id": "oZyXJwTgXJ1G"
      },
      "outputs": [],
      "source": [
        "pd.set_option('display.max_colwidth', None)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "H6zdmFS0vlww"
      },
      "outputs": [],
      "source": [
        "# ─────────────────────────────────────────────────────────────\n",
        "# FINAL 2025 GOLD SYSTEM PROMPT\n",
        "# ─────────────────────────────────────────────────────────────\n",
        "SYSTEM_PROMPT = \"\"\"\n",
        "You are a world-class, high-precision clinical trial eligibility parser specialized in oncology interventional therapeutic trials. Your only job is to output perfect, strictly valid JSON using the exact schema below. Never add, remove, or rename any field. Never output explanations, markdown, or extra text.\n",
        "\n",
        "### MANDATORY SCHEMA (use EXACTLY this structure)\n",
        "{\n",
        "  \"trial_id\": null,\n",
        "  \"trial_category\": \"therapeutic_interventional\",\n",
        "  \"age\": {\"min\": 18, \"max\": null},\n",
        "  \"region_specific_age\": {\"japan_min\": null},\n",
        "  \"inclusion\": {\n",
        "    \"disease\": {\n",
        "      \"confirmed_by\": null,\n",
        "      \"cancer_type\": \"\",\n",
        "      \"histology_subtype\": \"\",\n",
        "      \"stage\": \"\",\n",
        "      \"stage_list\": [],\n",
        "      \"metastatic\": null,\n",
        "      \"measurable_disease_recist\": null,\n",
        "      \"biomarker_required\": []\n",
        "    },\n",
        "    \"performance_status\": {\n",
        "      \"scale\": null,\n",
        "      \"min\": null,\n",
        "      \"max\": null\n",
        "    },\n",
        "    \"life_expectancy_weeks\": null,\n",
        "    \"prior_therapy\": {\n",
        "      \"required\": [],\n",
        "      \"allowed\": [],\n",
        "      \"disallowed\": [],\n",
        "      \"max_lines_systemic\": null,\n",
        "      \"washout_weeks\": {\n",
        "        \"chemotherapy\": null,\n",
        "        \"targeted_therapy\": null,\n",
        "        \"immunotherapy\": null,\n",
        "        \"investigational\": null,\n",
        "        \"radiation\": null,\n",
        "        \"major_surgery\": null\n",
        "      }\n",
        "    },\n",
        "    \"brain_metastases\": null,\n",
        "    \"brain_mets_stable_duration_weeks\": null,\n",
        "    \"organ_function\": {\n",
        "      \"anc\": null,\n",
        "      \"platelets\": null,\n",
        "      \"hemoglobin_g_per_dl\": null,\n",
        "      \"creatinine_clearance_ml_min\": null,\n",
        "      \"bilirubin_x_uln\": null,\n",
        "      \"ast_alt_x_uln\": null,\n",
        "      \"albumin_g_per_dl\": null\n",
        "    },\n",
        "    \"cardiac\": {\n",
        "      \"qtcf_ms_max\": null,\n",
        "      \"recent_mi_months_exclusion\": null,\n",
        "      \"nyha_class_max\": null,\n",
        "      \"lvef_percent_min\": null\n",
        "    },\n",
        "    \"contraception_required\": null,\n",
        "    \"other_inclusions\": []\n",
        "  },\n",
        "  \"exclusion\": {\n",
        "    \"pregnant_or_breastfeeding\": null,\n",
        "    \"active_cns_metastases\": null,\n",
        "    \"uncontrolled_intercurrent_illness\": null,\n",
        "    \"grade_2_or_higher_neuropathy\": null,\n",
        "    \"history_of\": [],\n",
        "    \"concurrent_medications_disallowed\": [],\n",
        "    \"other_exclusions\": []\n",
        "  }\n",
        "}\n",
        "\n",
        "### STRICT RULES & CONVENTIONS (follow exactly)\n",
        "\n",
        "1. Age\n",
        "   - Default \"min\": 18 unless explicitly different\n",
        "   - Japan-specific pediatric trials → fill japan_min only\n",
        "\n",
        "2. Performance Status\n",
        "   - Convert everything to ECOG 0–5 scale\n",
        "   - Karnofsky 70–100 → ECOG 0–1 (\"min\": 0, \"max\": 1)\n",
        "   - Karnofsky ≥70 → \"max\": 1\n",
        "   - ECOG ≤1 → \"max\": 1\n",
        "   - Always fill \"scale\": \"ECOG\"\n",
        "\n",
        "3. Brain Metastases – ONLY use these 5 values:\n",
        "   null | \"excluded\" | \"allowed_if_asymptomatic\" | \"allowed_if_stable\" | \"allowed_if_treated_and_stable\"\n",
        "   - If stable duration specified → fill brain_mets_stable_duration_weeks\n",
        "   - \"Symptomatic\", \"uncontrolled\", \"requiring steroids\" → \"excluded\"\n",
        "\n",
        "4. Biomarkers\n",
        "   - Use exact wording from trial: \"ALK positive by FDA-approved test\", \"EGFR exon 19 del or L858R\", \"PD-L1 TPS ≥50%\", \"BRCA1/2 mutated\", \"MSI-H/dMMR\"\n",
        "\n",
        "5. Prior Therapy\n",
        "   - \"max_lines_systemic\" = total systemic lines (not including adjuvant)\n",
        "   - \"required\" = must have received\n",
        "   - \"disallowed\" = must NOT have received\n",
        "\n",
        "6. Lab Values – ALWAYS normalize\n",
        "   - Bilirubin ≤1.5 mg/dL → \"bilirubin_x_uln\": 1.5\n",
        "   - AST/ALT ≤3×ULN (≤5× if liver mets) → \"ast_alt_x_uln\": 3 + note exception in other_inclusions\n",
        "   - Hemoglobin ≥9 g/dL → \"hemoglobin_g_per_dl\": 9\n",
        "\n",
        "7. Life Expectancy\n",
        "   - ≥3 months = 12, ≥6 months = 24, ≥12 months = 52\n",
        "\n",
        "8. Contraception\n",
        "   - Any mention of highly effective contraception → \"contraception_required\": true\n",
        "\n",
        "9. cancer_type & histology_subtype\n",
        "   - cancer_type: \"non-small cell lung cancer\", \"hepatocellular carcinoma\", \"urothelial carcinoma\"\n",
        "   - histology_subtype: \"adenocarcinoma\", \"squamous\", \"small cell\", \"clear cell RCC\"\n",
        "\n",
        "10. NEVER leave critical fields null if information exists\n",
        "    - If ECOG mentioned → fill performance_status\n",
        "    - If any labs mentioned → fill organ_function\n",
        "    - If any prior therapy rules → fill prior_therapy\n",
        "\n",
        "11. other_inclusions / other_exclusions\n",
        "    - Short, precise bullets only\n",
        "    - Examples:\n",
        "      \"Archival tumor tissue required\"\n",
        "      \"Liver metastases: AST/ALT ≤5×ULN allowed\"\n",
        "      \"Able to swallow tablets\"\n",
        "      \"No active autoimmune disease requiring systemic treatment in past 2 years\"\n",
        "\n",
        "Only output raw JSON. No ```json wrapper, no extra characters, no thinking step.\n",
        "\n",
        "Now parse the following trial eligibility text:\n",
        "\"\"\"\n",
        "\n",
        "# ─────────────────────────────────────────────────────────────\n",
        "# FINAL PERFECT EXTRACTION FUNCTION\n",
        "# ─────────────────────────────────────────────────────────────\n",
        "def extract_eligibility_perfect(\n",
        "    text: str,\n",
        "    client,\n",
        "    model: str = \"meta-llama/llama-4-maverick-17b-128e-instruct\",\n",
        "    max_retries: int = 3\n",
        ") -> Dict[str, Any]:\n",
        "    \"\"\"\n",
        "    Final ultra-strict parser using your exact schema + rules.\n",
        "    Assumes input is a real therapeutic interventional trial.\n",
        "    Returns perfect JSON or raises exception.\n",
        "    \"\"\"\n",
        "    if not text or not text.strip():\n",
        "        raise ValueError(\"Empty eligibility text\")\n",
        "\n",
        "    for attempt in range(max_retries):\n",
        "        try:\n",
        "            response = client.chat.completions.create(\n",
        "                model=model,\n",
        "                messages=[\n",
        "                    {\"role\": \"system\", \"content\": SYSTEM_PROMPT},\n",
        "                    {\"role\": \"user\", \"content\": text}\n",
        "                ],\n",
        "                temperature=0.0,\n",
        "                top_p=1.0,\n",
        "                max_tokens=3000,\n",
        "                timeout=90\n",
        "            )\n",
        "\n",
        "            raw = response.choices[0].message.content.strip()\n",
        "\n",
        "            # Remove any accidental wrappers\n",
        "            raw = re.sub(r\"^```json\\s*\", \"\", raw, flags=re.IGNORECASE)\n",
        "            raw = re.sub(r\"^```\\s*\", \"\", raw)\n",
        "            raw = re.sub(r\"```$\", \"\", raw)\n",
        "            raw = raw.strip()\n",
        "\n",
        "            if not raw.startswith(\"{\"):\n",
        "                raise ValueError(\"Output does not start with {\")\n",
        "\n",
        "            # Find first complete JSON object\n",
        "            brace_level = 0\n",
        "            end_idx = None\n",
        "            for i, char in enumerate(raw):\n",
        "                if char == '{': brace_level += 1\n",
        "                if char == '}': brace_level -= 1\n",
        "                if brace_level == 0:\n",
        "                    end_idx = i + 1\n",
        "                    break\n",
        "            if end_idx is None:\n",
        "                raise ValueError(\"Unbalanced braces\")\n",
        "\n",
        "            json_str = raw[:end_idx]\n",
        "            result = json.loads(json_str)\n",
        "\n",
        "            # Basic validation\n",
        "            if not isinstance(result, dict) or \"inclusion\" not in result:\n",
        "                raise ValueError(\"Invalid top-level structure\")\n",
        "\n",
        "            # Final safety: ensure performance_status scale is ECOG\n",
        "            ps = result[\"inclusion\"].get(\"performance_status\", {})\n",
        "            if ps.get(\"scale\") in [None, \"\"]:\n",
        "                ps[\"scale\"] = \"ECOG\"\n",
        "\n",
        "            return result\n",
        "\n",
        "        except Exception as e:\n",
        "            print(f\"[Attempt {attempt + 1}] Failed: {e}\")\n",
        "            if attempt < max_retries - 1:\n",
        "                time.sleep(2 ** attempt)\n",
        "                continue\n",
        "            else:\n",
        "                raise RuntimeError(f\"Eligibility parsing failed after {max_retries} attempts\") from e\n",
        "\n",
        "    raise RuntimeError(\"extract_eligibility_perfect exited unexpectedly\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 16,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "09Lgs3a0vnib",
        "outputId": "7c01f76c-6400-4654-9b80-fd241c21a8bd"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "100%|██████████| 6/6 [00:54<00:00,  9.06s/it]\n"
          ]
        }
      ],
      "source": [
        "tqdm.pandas()\n",
        "\n",
        "df_1[\"eligibility_json\"] = df_1[\"Eligibility\"].progress_apply(\n",
        "    lambda x: extract_eligibility_perfect(x, client=client)\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "c47VtXbdztjy",
        "outputId": "44d7d035-3e34-47d5-eb07-337a295c5c49"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"df_1[[\\\"eligibility_json\\\",\\\"Eligibility\\\"] ]\",\n  \"rows\": 6,\n  \"fields\": [\n    {\n      \"column\": \"eligibility_json\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Eligibility\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) after platinum-containing chemotherapy regimen with or without thoracic radiotherapy * Limited stage or extensive stage SCLC * Measurable disease * At least 20 mm by conventional techniques OR * At least 10 mm with spiral CT scan * No pleural effusions, bone metastases, brain metastases, or abnormal radionucleotide scans as sole evidence of disease * No symptomatic or uncontrolled brain or leptomeningeal disease * Previously treated brain metastases allowed if neurologically stable PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-2 Hematopoietic: * WBC at least 2,500/mm\\\\^3 * Platelet count at least 70,000/mm\\\\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No symptomatic heart disease * No myocardial infarction within the past 6 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 1 month before, during, and for 2 months after study * No pre-existing retinal degenerative disease (e.g., retinitis pigmentosa or associated disorders) * No other serious concurrent illness * No other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ PRIOR CONCURRENT THERAPY: Chemotherapy: * At least 3 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens Endocrine therapy: * Concurrent steroids allowed at stable dose Radiotherapy: * No prior radiotherapy to study lesions Other: * At least 3 weeks since prior systemic retinoid or carotenoid therapy * No concurrent anticonvulsants\",\n          \"Key Inclusion Criteria: * Subjects with advanced or metastatic solid tumours who have completed treatment with first line therapy: 1. Epithelial ovarian, fallopian tube, or peritoneal cancer 2. Hepatocellular carcinoma 3. Non-small cell lung cancer 4. Urothelial cancer 5. Microsatellite instability high solid tumours, other than the above indications * Radiologic and/or biochemical evidence of disease progression * Completion of pre-treatment tumour biopsy * Must have measurable disease by RECIST v1.1 * Ambulatory with an ECOG 0-1 * Life expectancy \\u2265 6 months * Meet protocol-specified laboratory requirements Key Exclusion Criteria: * Chemotherapy or immunotherapy within treatment within 28 days of start of study treatment * Radiotherapy within treatment within 2 weeks of start of study treatment * Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor where subject was discontinued from that treatment due to a Grade 3 or higher immune-related toxicity * For NSCLC subjects: Known EGFR mutations or ALK rearrangements * Prior receipt of survivin-based vaccine(s) and/or immunotherapies * Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer * Clinical ascites or pleural fluid that cannot be managed * Malignant bowel obstruction or recent history of bowel obstruction * For OvCa, subjects with any single lesion greater than 5 cm * Autoimmune disease requiring treatment within the last two years (except replacement therapy) * Recent history of thyroiditis * Any history of (non-infectious) pneumonitis that required steroid therapy or current pneumonitis * Presence of a serious acute or chronic infection * Active CNS metastases and/or carcinomatous meningitis * GI condition that might limit absorption of oral agents * Allogenic tissue/solid organ transplant * Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months * Ongoing treatment with steroid therapy or other immunosuppressive * Receipt of live attenuated vaccines * Acute or chronic skin and/or microvascular disorders * Edema or lymphedema in the lower limbs \\\\> grade 2 * Severe hypersensitivity (\\u2265 Grade 3) to pembrolizumab\",\n          \"Inclusion Criteria: 1. Patients older than 20 years of age. 2. The first time to accept the target drug treatment (Iressa, Tarceva) treatment, diagnosis of lung cancer third or fourth stage of the women. 3. There are computer equipment at home to play the disc. 4. can speak, write, read Chinese, clear consciousness, no cognitive impairment. 5. In the medical center of Taipei, a medical department, medical or surgical clinic for treatment. Exclusion Criteria: * none\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-de7cc514-519f-437b-81d6-f98c906ee87d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>eligibility_json</th>\n",
              "      <th>Eligibility</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'histology or cytology', 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'recurrent', 'stage_list': ['limited stage', 'extensive stage'], 'metastatic': None, 'measurable_disease_recist': True, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 2}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': ['platinum-containing chemotherapy regimen'], 'allowed': ['thoracic radiotherapy', 'steroids at stable dose'], 'disallowed': [], 'max_lines_systemic': 2, 'washout_weeks': {'chemotherapy': 3, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'allowed_if_treated_and_stable', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': 70000, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': 60, 'bilirubin_x_uln': 1.5, 'ast_alt_x_uln': 2, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': 6, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['WBC at least 2,500/mm^3', 'Creatinine no greater than 1.5 mg/dL or creatinine clearance at least 60 mL/min']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ', 'pre-existing retinal degenerative disease'], 'concurrent_medications_disallowed': ['anticonvulsants', 'systemic retinoid or carotenoid therapy'], 'other_exclusions': ['symptomatic heart disease']}}</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) after platinum-containing chemotherapy regimen with or without thoracic radiotherapy * Limited stage or extensive stage SCLC * Measurable disease * At least 20 mm by conventional techniques OR * At least 10 mm with spiral CT scan * No pleural effusions, bone metastases, brain metastases, or abnormal radionucleotide scans as sole evidence of disease * No symptomatic or uncontrolled brain or leptomeningeal disease * Previously treated brain metastases allowed if neurologically stable PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-2 Hematopoietic: * WBC at least 2,500/mm\\^3 * Platelet count at least 70,000/mm\\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No symptomatic heart disease * No myocardial infarction within the past 6 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 1 month before, during, and for 2 months after study * No pre-existing retinal degenerative disease (e.g., retinitis pigmentosa or associated disorders) * No other serious concurrent illness * No other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ PRIOR CONCURRENT THERAPY: Chemotherapy: * At least 3 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens Endocrine therapy: * Concurrent steroids allowed at stable dose Radiotherapy: * No prior radiotherapy to study lesions Other: * At least 3 weeks since prior systemic retinoid or carotenoid therapy * No concurrent anticonvulsants</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': '', 'histology_subtype': '', 'stage': 'advanced or metastatic', 'stage_list': [], 'metastatic': True, 'measurable_disease_recist': True, 'biomarker_required': ['microsatellite instability high']}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': 24, 'prior_therapy': {'required': ['first line therapy'], 'allowed': [], 'disallowed': [], 'max_lines_systemic': 1, 'washout_weeks': {'chemotherapy': 4, 'targeted_therapy': None, 'immunotherapy': 4, 'investigational': None, 'radiation': 2, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': 6, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Completion of pre-treatment tumour biopsy required', 'Radiologic and/or biochemical evidence of disease progression']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['prior therapy with anti-PD-1/PD-L1/PD-L2 agent with Grade 3 or higher immune-related toxicity', 'survivin-based vaccine(s) and/or immunotherapies', 'thyroiditis', 'non-infectious pneumonitis requiring steroid therapy', 'bowel obstruction', 'cerebrovascular event within 6 months', 'myocardial infarction within 6 months', 'allogenic tissue/solid organ transplant'], 'concurrent_medications_disallowed': ['steroid therapy or other immunosuppressive', 'live attenuated vaccines'], 'other_exclusions': ['Clinical ascites or pleural fluid that cannot be managed', 'Malignant bowel obstruction', 'For OvCa, any single lesion greater than 5 cm', 'Autoimmune disease requiring treatment within the last two years (except replacement therapy)', 'GI condition that might limit absorption of oral agents', 'Acute or chronic skin and/or microvascular disorders', 'Edema or lymphedema in the lower limbs &gt; grade 2', 'Severe hypersensitivity (≥ Grade 3) to pembrolizumab']}}</td>\n",
              "      <td>Key Inclusion Criteria: * Subjects with advanced or metastatic solid tumours who have completed treatment with first line therapy: 1. Epithelial ovarian, fallopian tube, or peritoneal cancer 2. Hepatocellular carcinoma 3. Non-small cell lung cancer 4. Urothelial cancer 5. Microsatellite instability high solid tumours, other than the above indications * Radiologic and/or biochemical evidence of disease progression * Completion of pre-treatment tumour biopsy * Must have measurable disease by RECIST v1.1 * Ambulatory with an ECOG 0-1 * Life expectancy ≥ 6 months * Meet protocol-specified laboratory requirements Key Exclusion Criteria: * Chemotherapy or immunotherapy within treatment within 28 days of start of study treatment * Radiotherapy within treatment within 2 weeks of start of study treatment * Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor where subject was discontinued from that treatment due to a Grade 3 or higher immune-related toxicity * For NSCLC subjects: Known EGFR mutations or ALK rearrangements * Prior receipt of survivin-based vaccine(s) and/or immunotherapies * Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer * Clinical ascites or pleural fluid that cannot be managed * Malignant bowel obstruction or recent history of bowel obstruction * For OvCa, subjects with any single lesion greater than 5 cm * Autoimmune disease requiring treatment within the last two years (except replacement therapy) * Recent history of thyroiditis * Any history of (non-infectious) pneumonitis that required steroid therapy or current pneumonitis * Presence of a serious acute or chronic infection * Active CNS metastases and/or carcinomatous meningitis * GI condition that might limit absorption of oral agents * Allogenic tissue/solid organ transplant * Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months * Ongoing treatment with steroid therapy or other immunosuppressive * Receipt of live attenuated vaccines * Acute or chronic skin and/or microvascular disorders * Edema or lymphedema in the lower limbs \\&gt; grade 2 * Severe hypersensitivity (≥ Grade 3) to pembrolizumab</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'histology or cytology', 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'limited or extensive', 'stage_list': ['LS-SCLC', 'ES-SCLC'], 'metastatic': None, 'measurable_disease_recist': True, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': 12, 'prior_therapy': {'required': ['platinum-containing dual-drug chemotherapy'], 'allowed': [], 'disallowed': ['immune checkpoint proteins/antibody/medicine'], 'max_lines_systemic': 1, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'allowed_if_treated_and_stable', 'brain_mets_stable_duration_weeks': 12, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['No radiotherapy contraindications', 'At least one extracranial measurable lesion (RECIST v1.1)', 'For lesions that have received radiotherapy, progression after radiotherapy must be confirmed']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': ['autoimmune diseases', 'HIV infection', 'alcoholism or drug abuse', 'grade 3 or above radiation pneumonitis'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Active chronic hepatitis B or active hepatitis C', 'Serious hypersensitive reaction to monoclonal antibodies', 'History of uncontrolled allergic asthma', 'Primary CNS tumors or meningeal metastases']}}</td>\n",
              "      <td>Inclusion Criteria: 1. Patients with histologically or cytologically confirmed LS-SCLC or ES-SCLC and experienced progression since first-line standard platinum containing dual-drug chemotherapy. 2. Patients whose initial diagnosis was limited must undergo radical chest radiotherapy and the time of tumor progression is not less than 3 months from the end of radiotherapy, or cannot receive radical chest radiotherapy due to specific reasons 3. At least one extracranial measurable lesion (RECIST v1.1), and for a lesion that has received radiotherapy, progression of the lesion after radiotherapy must be confirmed. 4. Patients with brain metastases are allowed to receive previous radiotherapy and their condition is stable, but the time to the end of radiotherapy must not be less than 3 months. 5. No radiotherapy contraindications were judged by the radiologist 6. ECOG performance status of 0 or 1. 7. Patients with life expectancy ≥ 3 months. 8. Patients must have adequate organ function. 9. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 6 months after last study drug administration. Exclusion Criteria: 1. Subjects known to have primary CNS tumors or meningeal metastases or unstable CNS metastases. 2. Patients with active autoimmune diseases or history of autoimmune diseases should be excluded. 3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment. 4. Known history of HIV infection. 5. Subjects with active chronic hepatitis B or active hepatitis C . 6. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma. 7. Known history of alcoholism or drugs abuse. 8. Subjects with history of radiation pneumonitis of grade 3 or above, regardless of recovered or not.</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 21, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'non-small cell lung cancer', 'histology_subtype': 'adenocarcinoma', 'stage': 'metastatic', 'stage_list': [], 'metastatic': True, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 1, 'max': 2}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': [], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': None, 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Asian ethnicity', 'Non-smoker', 'Pleural effusion', 'Fit for pleuroscopy and biopsy', 'Suitable for palliative chemotherapy or EGFR-TKI']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': None, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': [], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Non-Asian ethnicity', 'Smoker', 'Poor ECOG status', 'Unwilling to undergo pleuroscopy and biopsy', 'Not suitable for palliative chemotherapy or EGFR-TKI', 'Other histological subtypes and stages of disease']}}</td>\n",
              "      <td>Inclusion Criteria: * Asian ethnicity * Age \\&gt; 21 years old * Non-smoker * Metastatic pleural effusion due to lung adenocarcinoma * Good ECOG status (ECOG 1-2) fit to undergo pleuroscopy and biopsy and agreeable for palliative chemotherapy and or EGFR-TKI Exclusion Criteria: * Non-Asian ethnicity * Age \\&lt; 21 years old * Smoker * Subjects with poor ECOG status or unwilling to undergo pleuroscopy and biopsy * Subjects not suitable to receive palliative chemotherapy or EGFR-TKI * All other histological subtypes and stages of disease</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'I-III or IV without brain metastases', 'stage_list': ['I', 'II', 'III', 'IV'], 'metastatic': False, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': ['chemo-radiotherapy for stage I-III or chemotherapy for stage IV'], 'allowed': [], 'disallowed': [], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Sufficient proficiency in Dutch']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': ['prior radiotherapy to the brain', 'primary brain tumors', 'previous malignancy within 2 years ago except basal cell carcinoma or carcinoma in situ of the cervix'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Any systemic anticancer treatment during PCI or within 3 weeks before start PCI']}}</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cancer patients (stage I-III or stage IV without clinical or radiological evidence of brain metastases) candidate for PCI, i.e. without progressive disease after chemo-radiotherapy in stage I-III or after a remission after chemotherapy in stage IV * Sufficient proficiency in Dutch Exclusion Criteria: * Prior radiotherapy to the brain * Clinical evidence for brain metastases or primary brain tumors- Evidence of progressive extracranial metastatic disease * Previous malignancy \\&lt; 2 years ago except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix * Any systemic anticancer treatment during PCI or within 3 weeks before start PCI * Pregnancy or lactation</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 20, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'non-small cell lung cancer', 'histology_subtype': '', 'stage': 'stage III or IV', 'stage_list': ['III', 'IV'], 'metastatic': None, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': ['prior EGFR TKI'], 'max_lines_systemic': 0, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': None, 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Able to speak, write, read Chinese', 'Clear consciousness, no cognitive impairment', 'Receiving treatment at Taipei medical center']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': None, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': [], 'concurrent_medications_disallowed': [], 'other_exclusions': []}}</td>\n",
              "      <td>Inclusion Criteria: 1. Patients older than 20 years of age. 2. The first time to accept the target drug treatment (Iressa, Tarceva) treatment, diagnosis of lung cancer third or fourth stage of the women. 3. There are computer equipment at home to play the disc. 4. can speak, write, read Chinese, clear consciousness, no cognitive impairment. 5. In the medical center of Taipei, a medical department, medical or surgical clinic for treatment. Exclusion Criteria: * none</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-de7cc514-519f-437b-81d6-f98c906ee87d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-de7cc514-519f-437b-81d6-f98c906ee87d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-de7cc514-519f-437b-81d6-f98c906ee87d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-6de527dd-6c92-40dd-87cb-b561cf8b0550\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-6de527dd-6c92-40dd-87cb-b561cf8b0550')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-6de527dd-6c92-40dd-87cb-b561cf8b0550 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     eligibility_json  \\\n",
              "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                {'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'histology or cytology', 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'recurrent', 'stage_list': ['limited stage', 'extensive stage'], 'metastatic': None, 'measurable_disease_recist': True, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 2}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': ['platinum-containing chemotherapy regimen'], 'allowed': ['thoracic radiotherapy', 'steroids at stable dose'], 'disallowed': [], 'max_lines_systemic': 2, 'washout_weeks': {'chemotherapy': 3, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'allowed_if_treated_and_stable', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': 70000, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': 60, 'bilirubin_x_uln': 1.5, 'ast_alt_x_uln': 2, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': 6, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['WBC at least 2,500/mm^3', 'Creatinine no greater than 1.5 mg/dL or creatinine clearance at least 60 mL/min']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ', 'pre-existing retinal degenerative disease'], 'concurrent_medications_disallowed': ['anticonvulsants', 'systemic retinoid or carotenoid therapy'], 'other_exclusions': ['symptomatic heart disease']}}   \n",
              "1  {'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': '', 'histology_subtype': '', 'stage': 'advanced or metastatic', 'stage_list': [], 'metastatic': True, 'measurable_disease_recist': True, 'biomarker_required': ['microsatellite instability high']}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': 24, 'prior_therapy': {'required': ['first line therapy'], 'allowed': [], 'disallowed': [], 'max_lines_systemic': 1, 'washout_weeks': {'chemotherapy': 4, 'targeted_therapy': None, 'immunotherapy': 4, 'investigational': None, 'radiation': 2, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': 6, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Completion of pre-treatment tumour biopsy required', 'Radiologic and/or biochemical evidence of disease progression']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': True, 'grade_2_or_higher_neuropathy': None, 'history_of': ['prior therapy with anti-PD-1/PD-L1/PD-L2 agent with Grade 3 or higher immune-related toxicity', 'survivin-based vaccine(s) and/or immunotherapies', 'thyroiditis', 'non-infectious pneumonitis requiring steroid therapy', 'bowel obstruction', 'cerebrovascular event within 6 months', 'myocardial infarction within 6 months', 'allogenic tissue/solid organ transplant'], 'concurrent_medications_disallowed': ['steroid therapy or other immunosuppressive', 'live attenuated vaccines'], 'other_exclusions': ['Clinical ascites or pleural fluid that cannot be managed', 'Malignant bowel obstruction', 'For OvCa, any single lesion greater than 5 cm', 'Autoimmune disease requiring treatment within the last two years (except replacement therapy)', 'GI condition that might limit absorption of oral agents', 'Acute or chronic skin and/or microvascular disorders', 'Edema or lymphedema in the lower limbs > grade 2', 'Severe hypersensitivity (≥ Grade 3) to pembrolizumab']}}   \n",
              "2                                                                                                                                                                                                                                                                                                                                                                                                  {'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'histology or cytology', 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'limited or extensive', 'stage_list': ['LS-SCLC', 'ES-SCLC'], 'metastatic': None, 'measurable_disease_recist': True, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': 12, 'prior_therapy': {'required': ['platinum-containing dual-drug chemotherapy'], 'allowed': [], 'disallowed': ['immune checkpoint proteins/antibody/medicine'], 'max_lines_systemic': 1, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'allowed_if_treated_and_stable', 'brain_mets_stable_duration_weeks': 12, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['No radiotherapy contraindications', 'At least one extracranial measurable lesion (RECIST v1.1)', 'For lesions that have received radiotherapy, progression after radiotherapy must be confirmed']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': ['autoimmune diseases', 'HIV infection', 'alcoholism or drug abuse', 'grade 3 or above radiation pneumonitis'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Active chronic hepatitis B or active hepatitis C', 'Serious hypersensitive reaction to monoclonal antibodies', 'History of uncontrolled allergic asthma', 'Primary CNS tumors or meningeal metastases']}}   \n",
              "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           {'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 21, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'non-small cell lung cancer', 'histology_subtype': 'adenocarcinoma', 'stage': 'metastatic', 'stage_list': [], 'metastatic': True, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 1, 'max': 2}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': [], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': None, 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Asian ethnicity', 'Non-smoker', 'Pleural effusion', 'Fit for pleuroscopy and biopsy', 'Suitable for palliative chemotherapy or EGFR-TKI']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': None, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': [], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Non-Asian ethnicity', 'Smoker', 'Poor ECOG status', 'Unwilling to undergo pleuroscopy and biopsy', 'Not suitable for palliative chemotherapy or EGFR-TKI', 'Other histological subtypes and stages of disease']}}   \n",
              "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   {'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'small cell lung cancer', 'histology_subtype': '', 'stage': 'I-III or IV without brain metastases', 'stage_list': ['I', 'II', 'III', 'IV'], 'metastatic': False, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': ['chemo-radiotherapy for stage I-III or chemotherapy for stage IV'], 'allowed': [], 'disallowed': [], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': 'excluded', 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Sufficient proficiency in Dutch']}, 'exclusion': {'pregnant_or_breastfeeding': True, 'active_cns_metastases': True, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': ['prior radiotherapy to the brain', 'primary brain tumors', 'previous malignancy within 2 years ago except basal cell carcinoma or carcinoma in situ of the cervix'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['Any systemic anticancer treatment during PCI or within 3 weeks before start PCI']}}   \n",
              "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          {'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 20, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': None, 'cancer_type': 'non-small cell lung cancer', 'histology_subtype': '', 'stage': 'stage III or IV', 'stage_list': ['III', 'IV'], 'metastatic': None, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': None, 'max': None}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': ['prior EGFR TKI'], 'max_lines_systemic': 0, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': None, 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': None, 'other_inclusions': ['Able to speak, write, read Chinese', 'Clear consciousness, no cognitive impairment', 'Receiving treatment at Taipei medical center']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': None, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': [], 'concurrent_medications_disallowed': [], 'other_exclusions': []}}   \n",
              "\n",
              "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Eligibility  \n",
              "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) after platinum-containing chemotherapy regimen with or without thoracic radiotherapy * Limited stage or extensive stage SCLC * Measurable disease * At least 20 mm by conventional techniques OR * At least 10 mm with spiral CT scan * No pleural effusions, bone metastases, brain metastases, or abnormal radionucleotide scans as sole evidence of disease * No symptomatic or uncontrolled brain or leptomeningeal disease * Previously treated brain metastases allowed if neurologically stable PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-2 Hematopoietic: * WBC at least 2,500/mm\\^3 * Platelet count at least 70,000/mm\\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No symptomatic heart disease * No myocardial infarction within the past 6 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 1 month before, during, and for 2 months after study * No pre-existing retinal degenerative disease (e.g., retinitis pigmentosa or associated disorders) * No other serious concurrent illness * No other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ PRIOR CONCURRENT THERAPY: Chemotherapy: * At least 3 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens Endocrine therapy: * Concurrent steroids allowed at stable dose Radiotherapy: * No prior radiotherapy to study lesions Other: * At least 3 weeks since prior systemic retinoid or carotenoid therapy * No concurrent anticonvulsants  \n",
              "1  Key Inclusion Criteria: * Subjects with advanced or metastatic solid tumours who have completed treatment with first line therapy: 1. Epithelial ovarian, fallopian tube, or peritoneal cancer 2. Hepatocellular carcinoma 3. Non-small cell lung cancer 4. Urothelial cancer 5. Microsatellite instability high solid tumours, other than the above indications * Radiologic and/or biochemical evidence of disease progression * Completion of pre-treatment tumour biopsy * Must have measurable disease by RECIST v1.1 * Ambulatory with an ECOG 0-1 * Life expectancy ≥ 6 months * Meet protocol-specified laboratory requirements Key Exclusion Criteria: * Chemotherapy or immunotherapy within treatment within 28 days of start of study treatment * Radiotherapy within treatment within 2 weeks of start of study treatment * Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor where subject was discontinued from that treatment due to a Grade 3 or higher immune-related toxicity * For NSCLC subjects: Known EGFR mutations or ALK rearrangements * Prior receipt of survivin-based vaccine(s) and/or immunotherapies * Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer * Clinical ascites or pleural fluid that cannot be managed * Malignant bowel obstruction or recent history of bowel obstruction * For OvCa, subjects with any single lesion greater than 5 cm * Autoimmune disease requiring treatment within the last two years (except replacement therapy) * Recent history of thyroiditis * Any history of (non-infectious) pneumonitis that required steroid therapy or current pneumonitis * Presence of a serious acute or chronic infection * Active CNS metastases and/or carcinomatous meningitis * GI condition that might limit absorption of oral agents * Allogenic tissue/solid organ transplant * Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months * Ongoing treatment with steroid therapy or other immunosuppressive * Receipt of live attenuated vaccines * Acute or chronic skin and/or microvascular disorders * Edema or lymphedema in the lower limbs \\> grade 2 * Severe hypersensitivity (≥ Grade 3) to pembrolizumab  \n",
              "2                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion Criteria: 1. Patients with histologically or cytologically confirmed LS-SCLC or ES-SCLC and experienced progression since first-line standard platinum containing dual-drug chemotherapy. 2. Patients whose initial diagnosis was limited must undergo radical chest radiotherapy and the time of tumor progression is not less than 3 months from the end of radiotherapy, or cannot receive radical chest radiotherapy due to specific reasons 3. At least one extracranial measurable lesion (RECIST v1.1), and for a lesion that has received radiotherapy, progression of the lesion after radiotherapy must be confirmed. 4. Patients with brain metastases are allowed to receive previous radiotherapy and their condition is stable, but the time to the end of radiotherapy must not be less than 3 months. 5. No radiotherapy contraindications were judged by the radiologist 6. ECOG performance status of 0 or 1. 7. Patients with life expectancy ≥ 3 months. 8. Patients must have adequate organ function. 9. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 6 months after last study drug administration. Exclusion Criteria: 1. Subjects known to have primary CNS tumors or meningeal metastases or unstable CNS metastases. 2. Patients with active autoimmune diseases or history of autoimmune diseases should be excluded. 3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment. 4. Known history of HIV infection. 5. Subjects with active chronic hepatitis B or active hepatitis C . 6. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma. 7. Known history of alcoholism or drugs abuse. 8. Subjects with history of radiation pneumonitis of grade 3 or above, regardless of recovered or not.  \n",
              "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Inclusion Criteria: * Asian ethnicity * Age \\> 21 years old * Non-smoker * Metastatic pleural effusion due to lung adenocarcinoma * Good ECOG status (ECOG 1-2) fit to undergo pleuroscopy and biopsy and agreeable for palliative chemotherapy and or EGFR-TKI Exclusion Criteria: * Non-Asian ethnicity * Age \\< 21 years old * Smoker * Subjects with poor ECOG status or unwilling to undergo pleuroscopy and biopsy * Subjects not suitable to receive palliative chemotherapy or EGFR-TKI * All other histological subtypes and stages of disease  \n",
              "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Inclusion Criteria: * \\- Small Cell Lung Cancer patients (stage I-III or stage IV without clinical or radiological evidence of brain metastases) candidate for PCI, i.e. without progressive disease after chemo-radiotherapy in stage I-III or after a remission after chemotherapy in stage IV * Sufficient proficiency in Dutch Exclusion Criteria: * Prior radiotherapy to the brain * Clinical evidence for brain metastases or primary brain tumors- Evidence of progressive extracranial metastatic disease * Previous malignancy \\< 2 years ago except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix * Any systemic anticancer treatment during PCI or within 3 weeks before start PCI * Pregnancy or lactation  \n",
              "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Inclusion Criteria: 1. Patients older than 20 years of age. 2. The first time to accept the target drug treatment (Iressa, Tarceva) treatment, diagnosis of lung cancer third or fourth stage of the women. 3. There are computer equipment at home to play the disc. 4. can speak, write, read Chinese, clear consciousness, no cognitive impairment. 5. In the medical center of Taipei, a medical department, medical or surgical clinic for treatment. Exclusion Criteria: * none  "
            ]
          },
          "execution_count": 17,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df_1[[\"eligibility_json\",\"Eligibility\"] ].head(10)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "uhz-gvb9Fruf"
      },
      "outputs": [],
      "source": [
        "# df_1[[\"eligibility_json\",\"Eligibility\"]].iloc[11:20]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 18,
      "metadata": {
        "id": "jxnl-zq82JD1"
      },
      "outputs": [],
      "source": [
        "df_1_nice = df_1.copy()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 19,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fRU3nGGb0GSw",
        "outputId": "9a38c772-83e7-4c6a-c282-0e0a238d3de7"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Saved: mavrik_trials_parse+preview.csv\n"
          ]
        }
      ],
      "source": [
        "# ============= Save CSV ============\n",
        "csv_name = \"mavrik_trials_parse+preview.csv\"\n",
        "df_1_nice.to_csv(csv_name, index=False)\n",
        "print(\"Saved:\", csv_name)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 20,
      "metadata": {
        "id": "fE8humUjDc2y"
      },
      "outputs": [],
      "source": [
        "df_1_nice = pd.read_csv(csv_name)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 22,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 634
        },
        "id": "R7GJmsJIDc56",
        "outputId": "bacb6708-a1c7-40e2-aaf2-5375d8c3323a"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_1_nice"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-cb8dcc92-1964-43e4-92ae-22e7167e96d4\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Official_Title</th>\n",
              "      <th>Status</th>\n",
              "      <th>Start_Date</th>\n",
              "      <th>Primary_Completion</th>\n",
              "      <th>Study_Type</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>...</th>\n",
              "      <th>Min_Age</th>\n",
              "      <th>Max_Age</th>\n",
              "      <th>Lead_Sponsor</th>\n",
              "      <th>Brief_Summary</th>\n",
              "      <th>Eligibility</th>\n",
              "      <th>Primary_Measures</th>\n",
              "      <th>Secondary_Measures</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>elig_len</th>\n",
              "      <th>eligibility_json</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00009971</td>\n",
              "      <td>Fenretinide in Treating Patients With Recurren...</td>\n",
              "      <td>Phase II Trial Of Fenretinide (NSC-374551; IND...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2000-11</td>\n",
              "      <td>2005-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>32</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Phase II trial to study the effectiveness of f...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or c...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:fenretinide</td>\n",
              "      <td>1815</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT03836352</td>\n",
              "      <td>Study of an Immunotherapeutic, DPX-Survivac, i...</td>\n",
              "      <td>A Phase 2, Open-label, Multicenter, Study of a...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2018-12-21</td>\n",
              "      <td>2023-12-31</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>184</td>\n",
              "      <td>Ovarian Cancer, Hepatocellular Carcinoma, Non-...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ImmunoVaccine Technologies, Inc. (IMV Inc.)</td>\n",
              "      <td>This study will assess the safety and efficacy...</td>\n",
              "      <td>Key Inclusion Criteria: * Subjects with advanc...</td>\n",
              "      <td>Efficacy as measured by objective response rat...</td>\n",
              "      <td>Objective response rate | Duration of response...</td>\n",
              "      <td>OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...</td>\n",
              "      <td>2335</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT04421352</td>\n",
              "      <td>Safety and Tolerability Evaluation of Low-dose...</td>\n",
              "      <td>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2021-01-12</td>\n",
              "      <td>2023-12-22</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>11</td>\n",
              "      <td>Relapsed Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>CStone Pharmaceuticals</td>\n",
              "      <td>A Phase Ia/Ib Safety and Tolerability Evaluati...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients with histologi...</td>\n",
              "      <td>To determine the recommended radiation dose an...</td>\n",
              "      <td>Incidence of Adverse Events (AE) and Dose-Limi...</td>\n",
              "      <td>DRUG:CS1001</td>\n",
              "      <td>1904</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT01774526</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2010-12</td>\n",
              "      <td>2016-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>40</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>21 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National University Hospital, Singapore</td>\n",
              "      <td>Lung Cancer continues to be the major cause of...</td>\n",
              "      <td>Inclusion Criteria: * Asian ethnicity * Age \\&gt;...</td>\n",
              "      <td>Descriptive study of our patients with lung ad...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>OTHER:Characterise the molecular epidemiology ...</td>\n",
              "      <td>535</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT01780675</td>\n",
              "      <td>Hippocampus Avoidance PCI vs PCI</td>\n",
              "      <td>Prophylactic Cranial Irradiation With or Witho...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-04</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>168</td>\n",
              "      <td>Small Cell Lung Cancer, Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>The Netherlands Cancer Institute</td>\n",
              "      <td>Using Intensity Modulated radiotherapy it is p...</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cance...</td>\n",
              "      <td>neurocognitive decline</td>\n",
              "      <td>safety</td>\n",
              "      <td>RADIATION:Radiation Prophylactic Cranial Irrad...</td>\n",
              "      <td>741</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>NCT03231111</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2017-07-25</td>\n",
              "      <td>2018-07-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>60</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>20 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>National Taiwan University Hospital</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients older than 20 ...</td>\n",
              "      <td>skindex-29</td>\n",
              "      <td>NaN</td>\n",
              "      <td>OTHER:Preventive Multimedia Teaching Program</td>\n",
              "      <td>469</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>6 rows × 21 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-cb8dcc92-1964-43e4-92ae-22e7167e96d4')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-cb8dcc92-1964-43e4-92ae-22e7167e96d4 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-cb8dcc92-1964-43e4-92ae-22e7167e96d4');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-254cf438-c3b3-48d8-814d-ec3e5f71f2c7\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-254cf438-c3b3-48d8-814d-ec3e5f71f2c7')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-254cf438-c3b3-48d8-814d-ec3e5f71f2c7 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_e42b0140-ba14-406a-8523-67f86e9e8dd1\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df_1_nice')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_e42b0140-ba14-406a-8523-67f86e9e8dd1 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df_1_nice');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "        NCT_ID                                              Title  \\\n",
              "0  NCT00009971  Fenretinide in Treating Patients With Recurren...   \n",
              "1  NCT03836352  Study of an Immunotherapeutic, DPX-Survivac, i...   \n",
              "2  NCT04421352  Safety and Tolerability Evaluation of Low-dose...   \n",
              "3  NCT01774526  Molecular Epidemiology of Lung Adenocarcinoma ...   \n",
              "4  NCT01780675                   Hippocampus Avoidance PCI vs PCI   \n",
              "5  NCT03231111  The Effectiveness of Using Preventive Multimed...   \n",
              "\n",
              "                                      Official_Title                 Status  \\\n",
              "0  Phase II Trial Of Fenretinide (NSC-374551; IND...              COMPLETED   \n",
              "1  A Phase 2, Open-label, Multicenter, Study of a...  ACTIVE_NOT_RECRUITING   \n",
              "2  A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...              COMPLETED   \n",
              "3  Molecular Epidemiology of Lung Adenocarcinoma ...                UNKNOWN   \n",
              "4  Prophylactic Cranial Irradiation With or Witho...              COMPLETED   \n",
              "5  The Effectiveness of Using Preventive Multimed...                UNKNOWN   \n",
              "\n",
              "   Start_Date Primary_Completion      Study_Type  Phases  Enrollment  \\\n",
              "0     2000-11            2005-09  INTERVENTIONAL  PHASE2          32   \n",
              "1  2018-12-21         2023-12-31  INTERVENTIONAL  PHASE2         184   \n",
              "2  2021-01-12         2023-12-22  INTERVENTIONAL  PHASE1          11   \n",
              "3     2010-12            2016-12  INTERVENTIONAL     NaN          40   \n",
              "4     2013-04         2019-04-01  INTERVENTIONAL  PHASE3         168   \n",
              "5  2017-07-25         2018-07-01  INTERVENTIONAL     NaN          60   \n",
              "\n",
              "                                          Conditions  ...   Min_Age   Max_Age  \\\n",
              "0                                        Lung Cancer  ...  18 Years       NaN   \n",
              "1  Ovarian Cancer, Hepatocellular Carcinoma, Non-...  ...  18 Years       NaN   \n",
              "2                    Relapsed Small Cell Lung Cancer  ...  18 Years  75 Years   \n",
              "3                                        Lung Cancer  ...  21 Years       NaN   \n",
              "4                Small Cell Lung Cancer, Lung Cancer  ...  18 Years       NaN   \n",
              "5                                        Lung Cancer  ...  20 Years  80 Years   \n",
              "\n",
              "                                  Lead_Sponsor  \\\n",
              "0              National Cancer Institute (NCI)   \n",
              "1  ImmunoVaccine Technologies, Inc. (IMV Inc.)   \n",
              "2                       CStone Pharmaceuticals   \n",
              "3      National University Hospital, Singapore   \n",
              "4             The Netherlands Cancer Institute   \n",
              "5          National Taiwan University Hospital   \n",
              "\n",
              "                                       Brief_Summary  \\\n",
              "0  Phase II trial to study the effectiveness of f...   \n",
              "1  This study will assess the safety and efficacy...   \n",
              "2  A Phase Ia/Ib Safety and Tolerability Evaluati...   \n",
              "3  Lung Cancer continues to be the major cause of...   \n",
              "4  Using Intensity Modulated radiotherapy it is p...   \n",
              "5  The Effectiveness of Using Preventive Multimed...   \n",
              "\n",
              "                                         Eligibility  \\\n",
              "0  DISEASE CHARACTERISTICS: * Histologically or c...   \n",
              "1  Key Inclusion Criteria: * Subjects with advanc...   \n",
              "2  Inclusion Criteria: 1. Patients with histologi...   \n",
              "3  Inclusion Criteria: * Asian ethnicity * Age \\>...   \n",
              "4  Inclusion Criteria: * \\- Small Cell Lung Cance...   \n",
              "5  Inclusion Criteria: 1. Patients older than 20 ...   \n",
              "\n",
              "                                    Primary_Measures  \\\n",
              "0                                                NaN   \n",
              "1  Efficacy as measured by objective response rat...   \n",
              "2  To determine the recommended radiation dose an...   \n",
              "3  Descriptive study of our patients with lung ad...   \n",
              "4                             neurocognitive decline   \n",
              "5                                         skindex-29   \n",
              "\n",
              "                                  Secondary_Measures  \\\n",
              "0                                                NaN   \n",
              "1  Objective response rate | Duration of response...   \n",
              "2  Incidence of Adverse Events (AE) and Dose-Limi...   \n",
              "3                                                NaN   \n",
              "4                                             safety   \n",
              "5                                                NaN   \n",
              "\n",
              "                                       Interventions elig_len  \\\n",
              "0                                   DRUG:fenretinide     1815   \n",
              "1  OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...     2335   \n",
              "2                                        DRUG:CS1001     1904   \n",
              "3  OTHER:Characterise the molecular epidemiology ...      535   \n",
              "4  RADIATION:Radiation Prophylactic Cranial Irrad...      741   \n",
              "5       OTHER:Preventive Multimedia Teaching Program      469   \n",
              "\n",
              "                                    eligibility_json  \n",
              "0  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "1  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "2  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "3  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "4  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "5  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "\n",
              "[6 rows x 21 columns]"
            ]
          },
          "execution_count": 22,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "pd.reset_option('display.max_colwidth')\n",
        "df_1_nice"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "nZwmMWDgDgPK"
      },
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
